

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Association of Fatty Liver Index with risk of Incident Type 2 Diabetes by Metabolic Syndrome Status

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026949
Article Type:	Research
Date Submitted by the Author:	28-Sep-2018
Complete List of Authors:	Olubamwo, Olubunmi; Ita-Suomen yliopisto Terveystieteiden tiedekunta, Public Health and Clinical Nutrition Virtanen, Jyrki K.; Ita-Suomen yliopisto Kansanterveystiede ja kliininen ravitsemustiede, Public Health and Clinical Nutrition Pihlajämäki, Jussi; Public Health and Clinical Nutrition; Kuopio University Hospital, KYS , Clinical Nutrition and Obesity Center Tuomainen, Tomi-Pekka; Ita-Suomen yliopisto Kansanterveystiede ja kliininen ravitsemustiede, Public Health and Clinical Nutrition
Keywords:	EPIDEMIOLOGY, Hepatology < INTERNAL MEDICINE, Diabetes & endocrinology < INTERNAL MEDICINE, PREVENTIVE MEDICINE, PUBLIC HEALTH

SCHOLARONE™
Manuscripts

Peer Review Only

1
2
3 1 **Association of Fatty Liver Index with risk of Incident Type 2 Diabetes by Metabolic Syndrome**
4 2 **Status**

5
6 3 Olubunmi O. Olubamwo¹, Jyrki K. Virtanen¹, Jussi Pihlajamäki^{1,2}, Tomi-Pekka Tuomainen¹
7 4

8 5 ¹ Institute of Public Health and Clinical Nutrition, Faculty of Health Sciences, University of Eastern
9 6 Finland, Kuopio, Finland.

10 7 ² Clinical Nutrition and Obesity Center, Kuopio University Hospital, KYS Kuopio, Finland.
11 8

12 9
13 10
14 11
15 12
16 13
17 14 **Running head:** FLI and risk of T2D by MS status. Olubamwo et al.
18 15

19 16 **Word count:** main text 3864 words, abstract 267 words.
20 17
21 18
22 19
23 20
24 21
25 22
26 23
27 24
28 25
29 26
30 27
31 28
32 29
33 30
34 31
35 32
36 33
37 34
38 35
39 36
40 37
41 38
42 39
43 40
44 41
45 42
46 43
47 44
48 45
49 46
50 47
51 48
52 49
53 50
54 51
55 52
56 53
57 54
58 55
59 56
60 57

38 *Corresponding author:
39

40 Olubunmi O, Olubamwo
41 Institute of Public Health and Clinical Nutrition
42 Faculty of Health Sciences
43 University of Eastern Finland, Kuopio,
44 P.O.Box 1627, FI-70211 Kuopio, Finland.
45 E-mail : olubunmi.olubamwo@uef.fi Tel : +358 403552905.
46

1 ABSTRACT

2 **Background and Objective:** Fatty liver disease (FLD) is increasingly recognized as a predictor of
3 cardiometabolic risk. Our objective was to examine metabolic syndrome (MS) status affects the
4 association of FLD with incident Type-2 diabetes (T2D) in middle-aged men.

5 **Design and Participants:** In this prospective epidemiological study, our subjects were 1792 men
6 without diabetes at baseline in the Kuopio Ischaemic Heart Disease Risk Factor Study (KIHD)
7 cohort. Using fatty liver index (FLI), the association of baseline FLD with incident T2D was analyzed
8 in multivariable-adjusted Cox regression models, considering their MS statuses.

9 **Results:** During a mean follow-up of 19 years, 375 incident cases of T2D were recorded. In overall
10 analysis, in model adjusted for constitutional, lifestyle and inflammation biomarkers, for the high
11 (FLI \geq 60) vs low (FLI $<$ 30) FLI category, the hazard ratio (HR (95%CI)) was 3.68(2.80-4.82). The
12 association was attenuated, but maintained, with further adjustment for metabolic factors.
13 Including MS status instead of metabolic factors, the HRs (95%CI) were 2.63(1.92-3.59) for FLI \geq 60
14 and 1.77(1.35-2.31) for MS.

15 In MS-stratified analysis, FLI predicted T2D only among persons without MS.

16 In unstratified analysis with subjects categorized by FLI-MS, compared with persons with FLI $<$ 30
17 without MS, persons with FLI \geq 60 without MS had increased risk (HR= 3.19(2.26-4.52)). Persons
18 with FLI $<$ 30 and MS had greater risk (HR= 4.31(2.15-8.61)) and, persons with both FLI \geq 60 and MS
19 had the greatest risk (HR=4.66(3.42-6.35)).

20 **Conclusion:** Generally, FLD (FLI \geq 60) predicts T2D. It specifically predicted T2D among subjects
21 without MS but, not among subjects with MS, for whom MS alone already increases the risk. Both
22 FLI and MS can complement each other in screening and surveillance for persons at increased T2D
23 risk.

24

1
2
3 1 **KEY WORDS:** fatty liver index, fatty liver disease, type 2 diabetes, metabolic syndrome, predictor,
4
5 2 metabolic factors, Kuopio Ischaemic Heart Disease Risk Factor Study
6
7
8 3
9

10
11 4 **STRENGTHS AND LIMITATIONS OF THIS STUDY**
12

- 13 5 • The study is population-based and the design is prospective, with long follow-up.
14
15 6 • We adjusted for a range of constitutional factors, lifestyle factors and biomarkers keeping
16
17 in cognizance the components of both major exposure variables to avoid overadjustment.
18 7
19
20 8 • The study population comprised of men only.
21
22 9 • Fatty Liver Index used as a surrogate of fatty liver does not detect progression of fatty liver
23
24 disease.
25 10
26
27 11 • The statuses of the subjects with respect to viral hepatitis were not established at baseline,
28
29 although, viral hepatitis have remained low in the Finnish population.
30
31
32
33
34
35 14
36
37
38 15
39
40
41 16
42
43
44 17
45
46
47 18
48
49
50 19
51
52 20
53
54
55 21
56
57
58
59
60

1 INTRODUCTION / BACKGROUND

2 There is increasing recognition that fatty liver disease (FLD), also known as hepatic steatosis, is the
3 commonest cause of chronic liver disease worldwide and that it is associated with increased risk of
4 cardiovascular disease and Type 2 diabetes (T2D). Although the prevalence varies in different
5 populations, it is also on the rise. Recent estimates suggest a global prevalence of 25% among
6 adults, with the highest prevalence in the Middle East and South America and lowest in Africa [1].

7 The prevalence is estimated to be 24% in Europe and more than 30% in developed countries [1].

8 Approximately one third of FLD patients progress to steatohepatitis with fibrosis, which can
9 progress to cirrhosis, liver failure and hepatocellular carcinoma [1]. In addition, FLD is intimately
10 linked with metabolic diseases, including T2D and, it can be considered a predictor of metabolic
11 diseases, even in the non-obese population [2].

12 With this increasing recognition that FLD is a public health problem, there is growing interest in
13 FLD as a predictor of incident T2D as well [3]. A number of epidemiological reports suggest that
14 non-alcoholic fatty liver disease (NAFLD), diagnosed using either liver enzymes or ultrasound scan
15 (USS), is associated with an increase in T2D incidence [4, 5].

16 Liver biopsy, which is the gold standard for characterizing liver histology in patients with fatty liver,
17 is expensive and carries some morbidity and very rare mortality risks [6]. The fatty liver index (FLI),
18 an algorithm comprising of body mass index, waist circumference, gamma-glutamyl transferase
19 (GGT) and triglyceride concentrations, was developed by Bedogni et al., to predict the presence of
20 FLD. The algorithm has been widely validated, and is gaining acceptance [7, 8]. There has been
21 reports of association of high FLI (FLD) with incident T2D [9], [10]. However, with FLD being
22 intimately linked with metabolic diseases, it is not known if the predictive ability of FLD is

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 independent of presence of established metabolic syndrome (MS), a known potent predictor of
2 T2D.
3 Therefore, using FLI as a surrogate for FLD, we examined whether MS status affects the
4 association of FLD, with incident T2D in middle-aged men.

For peer review only

1

2 METHODS

3 **Study population:** Our study population consisted of participants in the Kuopio Ischaemic Heart
4 Disease Risk Factor Study (KIHD). The KIHD study is a prospective population-based study
5 designed to investigate risk factors for CVDs and related outcomes, in middle-aged and ageing
6 men, from Eastern Finland. The original study population consisted of an age-stratified sample of
7 2682 men. They were enrolled in the baseline examinations between March 1984 and December
8 1989. The men were 42, 48, 54, or 60 years of age at baseline. The study was approved by the
9 Research Ethics Committee of the University of Kuopio [11], and the subjects gave their written
10 consent.

11 **Data Collection:** Data were collected through self-administered questionnaires, interviews,
12 physical examinations, and various blood tests to determine physiological and biochemical
13 parameters [12, 13]. The self-administered questionnaires were used to collect data on medical
14 history, including history of type 2 diabetes, metabolic diseases, liver disease, etc., medication
15 history, family history of diabetes, and family history of CVD[12]. Data on lifestyle, including
16 physical activity, history of smoking habit, history of alcohol consumption, and diet, were also
17 collected [14]. Categorization of alcohol consumption was done according to standard guidelines
18 by the National Institute of Alcohol Abuse and Alcoholism [15] and Dietary Guidelines for
19 Americans 2010 [16] as already published [17].

20 The family history of CVD or diabetes was defined as positive if the father, mother, sister, or
21 brother of the subject had a history of CVD or diabetes. [12]. A subject was defined as a smoker if
22 he had ever smoked on a regular basis and had smoked cigarettes, cigars, or pipe within the

1
2
3 1 previous 30 days. Dietary intakes including fruit, berry and vegetable consumption were assessed
4
5 2 with 4-day food recording [18].
6
7

8 3 Physical examinations included anthropometric measurements and indices, vital signs, and
9
10 4 physiologic measurements. All physical measurements were measured following standard
11
12 5 protocol. Waist circumference was calculated as the mean of waist circumference taken at
13
14 6 maximal inspiration and that taken at maximal expiration. Body mass index (BMI) was computed
15
16 7 as the ratio of weight in Kg to the square of height in meters (kg/m²). Blood pressure, which was
17
18 8 measured by two separate nurses, was taken as the mean of, three measurements in supine, one
19
20 9 on standing and two in sitting position with 5-min intervals [19].
21
22
23

24
25 10 **Specimen collection and laboratory measurements-** Blood samples were collected between 08.00
26
27 11 and 10.00 hours after 3 days of abstinence from alcohol ingestion and 12 hours abstinence from
28
29 12 smoking and eating. Data on complete blood count, serum electrolytes, Homeostatic model
30
31 13 assessment of insulin resistance (HOMA1-IR), fasting glucose, lipoprotein fractions (including total
32
33 14 cholesterol, HDL cholesterol, LDL cholesterol, serum triglycerides), liver function tests including
34
35 15 albumin, gamma-glutamyl transferase, fibrinogen, ferritin, and biomarkers like C-reactive protein
36
37 16 (CRP), were each determined from appropriately collected and processed samples. Detailed
38
39 17 description of the KIHD has been published elsewhere [11].
40
41
42

43 18 **Included and excluded subjects:** The initial number of subjects at baseline was 2682. Of these, we
44
45 19 excluded 40 subjects with history of physician diagnosed liver or pancreas disease, and 162
46
47 20 subjects with history of diabetes. Of the remaining 2480 subjects, 1792 who had complete data for
48
49 21 FLI calculation, were included in the analyses.
50
51
52

53 22 **Measuring the components of the Fatty liver index:** We calculated FLI using the algorithm
54
55 23 developed by Bedogni et al [7]. The algorithm, incorporates four variables: BMI, waist
56
57
58
59
60

1 circumference, serum triglycerides, and serum gamma-glutamyl transferase (GGT), and is
 2 expressed as follows:

$$3 \quad \text{FLI} = \frac{(e^{0.953 \times \ln(\text{triglycerides})} + 0.139 \times \text{BMI} + 0.718 \times \ln(\text{ggt}) + 0.053 \times \text{waist circumference} - 15.745)}{(1 + e^{0.953 \times \ln(\text{triglycerides})} + 0.139 \times \text{BMI} + 0.718 \times \ln(\text{ggt}) + 0.053 \times \text{waist circumference} - 15.745)} \times 100$$

4 Where triglycerides is in mg/dl, waist circumference in cm, and BMI in Kg/m². We categorized FLI
 5 in accordance with Bedogni et al's categorization, as low FLI (<30), intermediate FLI (30-<60), and
 6 moderate-high FLI (>60), indicating no fatty liver, indeterminate, and fatty liver, respectively.

7 **Defining Metabolic Syndrome Status:** MS was defined in accordance with the harmonized criteria
 8 for diagnosis of MS [20]. The presence of any 3 of the following 5 risk factors constitutes a
 9 diagnosis of metabolic syndrome: waist circumference ≥120 cm; serum triglycerides ≥150 mg/dL
 10 (1.7 mmol/L) (or drug treatment for elevated triglycerides); HDL cholesterol <40 mg/dL (1.0
 11 mmol/L) (or drug treatment for reduced HDL cholesterol); blood pressure with systolic ≥130
 12 and/or diastolic ≥85 mm Hg (or antihypertensive drug treatment in a patient with a history of
 13 hypertension); fasting glucose ≥100 mg/dl (or drug treatment of elevated glucose), [20].

14 **Outcome Definitions:** We defined incident T2D outcomes as self-reported physician-set diagnosis
 15 of T2D and/or; fasting plasma glucose ≥7.0mmol/L or 2-h oral glucose tolerance test plasma
 16 glucose ≥11.1 mmol/L at re-examination rounds 4, 11, and 20 years after the baseline and; by
 17 record linkage to either the national hospital discharge registers or to the Social Insurance
 18 Institution of Finland register for reimbursement of medicine expenses used for T2D. T2D cases
 19 that were included were those coded in the Tenth International Classification of Diseases (ICD 10
 20 code numbers from E11.0 to E11.9).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Patient and public involvement:** The study was carried out at a non-patient research facility. All
2 the study participants were volunteers. Neither the study participants nor the public were
3 involved in the design of the study.

4
5 **Statistical Methods:** All statistical analyses were performed using SPSS software Version 21.0 for
6 Windows (IBM, Chicago, IL). In all analyses, two-sided alpha <0.05 was considered statistically
7 significant.

8 Descriptive analyses were performed to summarize baseline characteristics of participants
9 according to baseline FLI categories. For continuous variables, we used Jonckheere trend test to
10 test for linear trend across FLI categories. For categorical variables, we used Chi-Square test to test
11 for linear association across FLI categories. To make up for missing 0.4% values (spread across
12 50% of the variables and 13.4% of subjects), we used a regression based multiple imputation
13 method (40 iterations) according to guideline by Cheema 2014 [21].

14 After confirmation of proportionality of hazards, we proceeded with multivariable-adjusted Cox
15 proportional hazards analysis, to analyze the association of baseline FLI with incident T2D in
16 considering metabolic factors and the MS statuses of the subjects as follows:

17 First, we analyzed the association overall, adjusting for MS status. The models were as follows:

18 Model 1- Examination year, constitutional factors (age and family history of T2D), lifestyle factors
19 (smoking pack years, alcohol consumption, physical activity and, consumption of fruits, berries and
20 vegetables) and, inflammatory markers (C-reactive protein, leukocyte count, thrombocyte count).

21 Model 2- Model 1 variables plus metabolic factors (fasting glucose, insulin, HDL, LDL, systolic blood
22 pressure, diastolic blood pressure). Model 3- Model 1 variables plus MS status.

1
2
3 1 In sensitivity analyses of overall analysis, we excluded subjects with a high weekly alcohol
4
5 2 consumption of ≥ 168 g [17] before analyzing the association of FLI with T2D in multivariable
6
7 3 adjusted Cox proportional hazards as explained above.
8
9

10 4 Secondly, in stratified analyses, we stratified our population sample by MS status. We then
11
12 5 performed multivariable-adjusted Cox proportional hazards analysis with adjustment for
13
14 6 covariates to observe if the association of FLI with incident T2D differs by MS status in model 1 and
15
16 7 2 as explained above.
17
18
19

20 8 Thirdly, for clearer understanding of the relation of the associations considering both FL and MS
21
22 9 statuses, using the combination of FLI category and MS status as a composite variable, we
23
24 10 performed multivariable-adjusted Cox proportional hazards analysis on the study population with
25
26 11 adjustment for covariates as in model 1 above, to elaborate the variation of the association by MS
27
28 12 status.
29
30
31

32 13

33
34
35 14

36
37
38 15

39
40
41 16

42
43
44 17

45
46
47 18

48
49
50 19

51
52
53 20

54
55
56 21

1
2
3 1
4
5
6 2
7
8
9 3
10
11 4
12
13
14 5
15
16
17 6
18
19
20 7
21
22 8
23
24 9
25
26 10
27
28
29 11
30
31 12
32
33 13
34
35 14
36
37 15
38
39
40
41 16
42
43 17
44
45 18
46
47 19
48
49 20
50
51 21
52
53
54
55 22
56
57
58
59
60

RESULTS

Characteristics of the study population: The baseline characteristics of the study population (1792 men) according to FLI categories are shown in Table 1. In general, the mean values and proportions for subjects in the intermediate FLI category were in between estimates for the lowest (reference) FLI category and estimates for the highest FLI category. Compared with the low FLI category, men in the high FLI category had a greater proportion of subjects with family history of diabetes, and a greater proportion with family history of CVD. They consumed less fruit, berries and vegetables, had a higher proportion of heavy alcohol consumers, but a lower proportion of smokers. They had higher mean waist circumference and mean BMI and they were more likely to be hypertensive. They also had higher GGT levels, higher triglyceride, higher fasting insulin, higher blood glucose, lower HDL cholesterol and higher levels of markers of systemic inflammation.

Multivariable proportional hazards model analyses: During a mean (SD) follow-up of 18.8(6.6) years, there were 375 cases of incident T2D. The incidence rates for T2D were 11 cases per 1000 person-years. Significantly lower survival free of incident T2D was noted for participants in high baseline FLI category compared to the low (normal) FLI category at baseline (Log-rank < 0.001). Subjects in intermediate FLI category also separated clearly from those with Low FLI for incident T2D.

Relation between baseline Fatty Liver Index and incident T2D

1
2
3 1 **Overall analyses:** Table 2 shows the association of FLI with incident T2D. In model 1, the HRs for
4
5 2 incident T2D was 98% higher for the intermediate category, and 268% higher for the high FLI
6
7 3 category, when compared with the low category. The association was maintained, though
8
9 4 attenuated in model 2, and in model 3 with MS where high FLI category was associated with 163%
10
11 5 increased risk. MS was also independently associated with incident T2D in the model, with 77%
12
13 6 increased risk (HR (95%CI) 1.77(1.35-2.31)).

14
15
16 7 *Sensitivity analyses* - after exclusion of 241 men who were heavy alcohol consumers (Table 3), the
17
18 8 results were similar to those obtained in the analyses with the whole sample, as shown in Table 2.
19
20 9 Further exploration of the association of FLI with incident T2D across FLI categories of 10 (see
21
22 10 Figure 1) reveals steady increase in HR across the categories without any threshold areas. When
23
24 11 we analyzed our data with FLI as continuous variable, a unit increase in FLI was associated with
25
26 12 1.7% increase in HR (in the analyses with the whole sample), and 1.8% increase (after exclusion
27
28 13 heavy alcohol consumers), as shown in Tables 2 and 3.

29
30
31 14 **Stratified analyses:** Table 4 shows the results of Cox regression analysis when we stratified by MS
32
33 15 status. Among those without MS, when compared with those in the low FLI category, high FLI was
34
35 16 associated with over 100% increased risk of T2D. Among those with MS, when compared with
36
37 17 those in the low FLI category, high FLI was not associated with additional risk.

38
39 18 **Analysis with composite FLI-MS variable:** In additional sensitivity analyses, with the combination
40
41 19 of FLI category and MS status as composite exposure variable, when compared with subjects
42
43 20 having neither fatty liver nor MS, having high FLI with no MS was associated with 219% increase in
44
45 21 risk (the HR (95%CI) was 3.19(2.26-4.51)). Having normal FLI with MS was associated with 331%
46
47 22 increased risk (the HR (95%CI) was 4.31(2.15-8.61)) and, persons having high FLI and MS were at
48
49 23 greatest risk, with 366% increase in risk (HR (95%CI) 4.66(3.42-6.35)). The presence of MS was
50
51 24 associated with greater risk in intermediate and high FLI categories (the HRs (95%CI) were
52
53
54
55
56
57
58
59
60

1 3.77(2.50-5.70) for presence of MS with intermediate FLI category, and 4.66(3.42-6.35) for the
 2 presence of MS with high FLI category).

3
 4
 5 **Table 1 - Baseline characteristics of 1792 men according to fatty liver index (FLI) categories**

Characteristic	FLI<30	FLI=30-< 60	FLI≥60	P-trend*
	Mean (SD) or n (%) N=833	Mean (SD) or n (%) N=552	Mean (SD) or n (%) N=407	
FLI	16.2 (7.7)	43.3 (8.1)	76.8 (10.6)	<0.001
Constitutional factors				
Age in years	52.6 (5.6)	53.4 (5.5)	52.5 (5.6)	0.251
Family history of diabetes	212 (25.5%)	145 (27.8%)	108 (26.5%)	0.651
Family history of CVD	667 (80.1%)	459 (83.2%)	341 (83.8%)	0.072
Lifestyle factors				
Smoking pack years	7.5(16.0)	8.4(16.8)	6.8(13.6)	0.785
Alcohol consumption (g/week)	55 (89)	78 (117)	116 (165)	<0.001
Physical activity (Energy exp.) (kcal/day)	136(156)	147(175)	129(192)	0.36
Fruit, berry and vegetable consumption (g/day)	265 (171)	261 (148)	233 (147)	0.023

**Anthropometrics and
physiologic
measurements**

Mean waist circumference (cm)	83.9 (6.1)	92.7 (5.2)	101.8 (8.1)	<0.001
BMI (kg/m ²)	24.4 (2.0)	27.3 (1.9)	30.7 (3.1)	<0.001
Mean systolic bp	135.5(17.0)	135.7(17.8)	135.9(18.1)	<0.001
Mean diastolic bp	89.4(10.5)	88.5(10.6)	89.6(11.1)	<0.001
Hypertension	259 (31.1%)	275 (49.8%)	261 (64.1%)	<0.001
Biomarkers				
Insulin	8.3 (3.0)	11.2 (4.4)	16.6 (9.7)	<0.001
Glucose (mmol/L)	4.5 (0.4)	4.6 (0.5)	4.8 (0.5)	<0.001
HOMA1-IR insulin resistance	1.86 (0.71)	2.60 (1.10)	3.91 (2.30)	<0.001
Total cholesterol (mmol/L)	5.71 (1.07)	5.93 (1.02)	6.05 (1.00)	<0.001
HDL cholesterol (mmol/L)	1.38 (0.32)	1.25 (0.26)	1.20 (0.27)	<0.001
LDL cholesterol (mmol/L)	3.91 (1.01)	4.09 (0.97)	4.01 (0.93)	0.04
Triglycerides (mmol/L)	0.94 (0.40)	1.35 (0.62)	1.93 (1.02)	<0.001
Gamma-glutamyl transferase (U/L)	18 (11)	28 (20)	51 (47)	<0.001
Albumin	42 (4)	42 (4)	43 (3)	<0.001

C- reactive protein (m/L)	1.86 (4.46)	2.61 (4.54)	3.15 (4.26)	<0.001
Ferritin (µg/L)	128 (100)	172 (157)	235 (186)	<0.001
Fibrinogen g/L	2.92 (0.58)	3.06 (0.57)	3.10 (0.55)	<0.001
Leukocyte count x10 ⁹ /L	5.4 (1.6)	5.7 (1.6)	5.9 (1.6)	<0.001
Metabolic syndrome and medication use history				
Metabolic syndrome	29 (3.5%)	91 (16.5%)	238 (58.5%)	<0.001
Drug for high cholesterol	7 (0.84%)	2 (0.36%)	6 (1.47%)	0.509
Drug for hypertension	111 (13.32%)	127 (23.05%)	141(34.56%)	<0.001

*Jonckheere trend test for continuous variable. Chi-Square linear-by-linear association for categorical variables. bp-
blood pressure

DIABETES PREDICTION

Table 2 – General association of baseline fatty liver index (FLI) with incident type 2 diabetes

FLI	Number of subjects (%) with T2D (IR)	Model 1 HR (95% CI)	Model 2 HR (95% CI)	Model 3 HR (95% CI)
FLI*	1792 (20.9) (11)	1.022(1.018-1.027)	1.013(1.007-1.018) ^a	1.017(1.012-1.022) ^b
FLI category				
≤30 (Ref.)	833 (12.1) (6)	1.000	1.000	1.000
30-<60	552 (22.6) (12)	1.98(1.52-2.59)	1.42(1.07-1.88)	1.81(1.38-2.37)
≥60	407 (36.6) (22)	3.68(2.80-4.82)	2.134(1.56-2.93) ^a	2.63(1.92-3.59) ^b
P-trend	-	<0.001	<0.001	<0.001

*FLI uncategorized, HR – hazard ratio. CI – confidence interval. T2D – type 2 diabetes, IR – Incidence rate per 1000 person-years

Model 1: FLI, age, examination date, family history of diabetes, smoking pack years, alcohol consumption per week, physical activity, fruit-berry-vegetable consumption, C-reactive protein, leukocytes albumin, fibrinogen, and ferritin.

Model 2: Model 1 plus systolic blood pressure, diastolic blood pressure, insulin, fasting glucose, LDL, and HDL.

Model 3: Model 1 plus metabolic syndrome status.

^a Other independent predictors of T2D in the model were family history of diabetes, serum ferritin, hypertension, serum insulin, and glucose.

^b Other independent predictors of T2D in the model were family history of diabetes, serum ferritin and metabolic syndrome status. HR metabolic syndrome = 1.77(1.35-2.31).

Table 3 – Association of baseline fatty liver index with incident type 2 diabetes after excluding men with high alcohol intake

FLI	Number of subjects (% with T2D) (IR)	Model 1 HR (95% CI)	Model 2 HR (95% CI)	Model 3 HR (95% CI)
FLI*	1548(20.9) (11)	1.023(1.018-1.027)	1.014(1.008-1.019)	1.018(1.012-1.024)
FLI category				
≤30 (Ref.)	771(12.5) (6)	1.000	1.000	1.000
30-<60	472(23.1) (12)	1.96(1.48-2.60)	1.43(1.06-1.93)	1.78(1.33-2.37)
≥60	305(38.7) (23)	3.61(2.71-4.81)	2.21(1.57-3.10)	2.63(1.89-3.66)
P-trend	-	<0.001	<0.001	<0.001

FLI – fatty liver index, FLI* - FLI uncategorized, HR – hazard ratio. CI – confidence interval. T2D – type 2 diabetes, IR – Incidence rate per 1000 person-years

Model 1: FLI, age, examination date, family history of diabetes, smoking pack years, alcohol consumption per week, physical activity, fruit-berry-vegetable consumption, C-reactive protein, leukocytes albumin, fibrinogen, and ferritin.
Model 2: Model 1 plus systolic blood pressure, diastolic blood pressure, insulin, fasting glucose, LDL, and HDL.
Model 3: Model 1 plus metabolic syndrome status.

^a Other independent predictors of T2D in the model were family history of diabetes, serum ferritin, hypertension, serum insulin, and fasting glucose.

^b Other independent predictors of T2D in the model were family history of diabetes, serum ferritin and metabolic syndrome status. HR metabolic syndrome = 1.65(1.24-2.21).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 4 – Association of fatty liver index (FLI) with incident type 2 diabetes by metabolic syndrome status (sub-analyses)

No metabolic syndrome	Number of subjects (% with T2D) (IR)	Model 1 HR(95%CI)	Model 2 HR(95%CI)
FLI*	1427(16.7) (9)	1.021 (1.015- 1.027)	1.017 (1.009- 1.024) ^a
FLI category			
≤30 (Ref.)	803(11.5) (6)	1.00	1.00 ^b
30-<60	456(20.0) (11)	1.81(1.33-2.46)	1.40(1.01-1.94)
≥60	168(33.3) (18)	3.07(2.14-4.41)	2.38(1.58-3.58)
p-trend		<0.001	<0.001
Metabolic syndrome	Number of subjects (% with T2D) (IR)	Model 1 HR(95%CI)	Model 2 HR(95%CI)
FLI*	358(37.7)(24)	1.007(0.997-1.016)	1.003(0.992- 1.014) ^c
FLI category			
≤30 (Ref.)	29(31.0) (23)	1.000	1.000 ^d
30-<60	91(36.3) (21)	0.77(0.35-1.70)	0.95(0.41-2.24)
≥60	238(39.1) (25)	1.02(0.49-2.16)	1.23 (0.54-2.82)
p-trend		0.42	0.42
Category by FLI and MS status	Number of subjects (% with T2D) (IR)	Model 1 HR(95%CI)	

FLI \leq 30 MS ⁻	803(11.5) (6)	1.000	-
FLI30-<60MS ⁻	456(20.0) (11)	1.79(1.33-2.41)	-
FLI \geq 60MS ⁻	168(33.3) (18)	3.19(2.26-4.51)	-
FLI \leq 30 MS ⁺	29(31.0) (23)	4.31(2.15-8.61)	-
FLI30-<60MS ⁺	91(36.3) (21)	3.77(2.50-5.70)	-
FLI \geq 60MS ⁺	238(39.1) (25)	4.66(3.42-6.35)	-

1 *FLI uncategorized, Ref – reference. HR – hazard ratio. CI – confidence interval. T2D – type 2 diabetes, IR – Incidence
 2 rate per 1000 person-years

3 †Statistically significant at P \leq 0.05. MS – Metabolic syndrome. MS⁻ - Metabolic syndrome negative. MS⁺ - Metabolic
 4 syndrome positive.

5 Model 1: FLI, age, examination date, family history of diabetes, smoking pack years, alcohol consumption per week,
 6 physical activity, fruit-berry-vegetable consumption, C-reactive protein, leukocytes thrombocytes, fibrinogen, and
 7 ferritin.

8 Model 2: Model 1 plus systolic blood pressure, diastolic blood pressure, insulin, fasting glucose, LDL, and HDL

9 ^a Other independent predictors of T2D in the model were serum ferritin and insulin.

10 ^b Other independent predictors of T2D in the model were serum ferritin and insulin.

11 ^c Independent predictors of T2D in the model were fasting glucose and insulin.

12 ^d Independent predictors of T2D in the model were fasting glucose and insulin.

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

15 Figure 1 – Graph of FLI and risk of incident T2D.

1

2 DISCUSSION

3 We examined the association of FLI, as a surrogate of fatty liver, with incident T2D in a population
4 of middle-aged men, considering the baseline MS status. Specifically, we found that although FLD
5 assessed by FLI predicts risk of T2D in the whole population, the association was strongest among
6 those without MS at baseline.

7 Few studies have investigated the association of baseline FLI as categorized by Bedogni et al., with
8 incident T2D [10, 22]. Jager et al.[22] and Onat et al. [10], studied the association of FLI with
9 incident T2D in healthy populations, followed up for eight years. Nishi et al.[23], studied the
10 association of FLI with incident T2D in a population of prediabetic subjects followed up for three
11 years[23].

12 A few studies, Balkau et al.[24] and Jung et al.[9] also reported the association of FLI with incident
13 T2D using FLI categorization different from that proposed by Bedogni et al. [9, 24]. Because
14 previous studies on the association of FLI with incident T2D have adjusted for different groups of
15 variables in their multivariable analyses, we are careful in our comparison of findings.

16 Our finding that high FLI (FLI \geq 60) indicating fatty liver, as compared with low FLI(FLI<30) is
17 associated with increased risk independent of constitutional and lifestyle factors, agrees with
18 findings from previous studies by Jager et al.[22] and Onat et al.[10]. We found a 2 to 3-fold
19 increased risk in our multivariable adjusted models. However, Jager et al., reported 11-fold
20 increase while Onat et al reported a 5-fold increase. Our finding, that FLI 30-<60 is also associated
21 with increased risk of T2D, is also in line with reports by Jager et al.

22 Our finding that high FLI is associated with incident T2D even after adjusting for metabolic factors,
23 agrees with reports from Onat et al.[10], Balkau et al.[24] and Jung et al. [9], each of which used

1 different cut-off points in categorizing FLI. Balkau et al. used FLI <20 and FLI ≥70 as lower and
2 upper cut-off points, and adjusted for glucose, insulin, and hypertension. Jung et al, used FLI<20
3 and FLI ≥60 as lower and upper cut-off points. When we analyzed our data using these cut-off
4 points, the results (data not shown) did not differ markedly from what we present here.

5 Indeed, ultrasound diagnosed NAFLD has been shown to be associated with incident T2D and, the
6 association is not affected by adjustment for metabolic syndrome [5]. However, the predictability
7 of T2D independent of MS using FLI needs to be clarified.

8 We are unable to compare our findings on association of FLI with incident T2D in view of MS status
9 of the subjects, with previous studies on the association between FLI and incident T2D because
10 previous studies on the association did not consider the MS status of the subjects. However, our
11 finding, in our man analysis, that high FLI category is associated with increased risk of incident T2D
12 after adjusting for of MS status agrees with the report by Shibata et al. [25]. Shibata et al. found
13 that the presence of fatty liver, as diagnosed by ultrasonography, is associated with increased risk
14 of T2D when compared with those without fatty liver after adjusting for age, BMI, smoking status,
15 physical activity, and MS status [25].

16 The finding of similar results, after excluding men who were heavy consumers of alcohol, indicates
17 that our findings are also applicable to NAFLD. However, the relative contribution of heavy ethanol
18 intake in the pathogenesis of fatty liver is still uncertain [26].

19 It is remarkable that, when we stratified by MS status, the association of high FLI with incident T2D
20 did not reach statistical significance among subjects with MS, despite the fact that increasing
21 proportions of subjects with MS developed T2D across the FLI categories. This suggests that
22 among persons with MS, which is already a cluster of risk factors for T2D (including
23 hyperglycaemia), high FLI is likely not associated with significantly higher risk than that due to

1 positive MS status alone. It also suggests that the MS status was an effect modifier in the overall
2 analysis.

3 Notwithstanding, our findings from the analysis with FLI-MS composite variable, are noteworthy. It
4 appears that FLI predicts risk of T2D in a dose-dependent manner among subjects without MS but
5 among subjects with MS, it does not predict risk of T2D in a dose-dependent manner. The
6 additional risk associated with high FLI appears less than that associated with MS positive status.
7 Therefore, the greatest risk was in subjects with both fatty liver and MS positivity. Our finding that
8 the presence of MS appears to be associated with higher risks than high FLI, may be consistent
9 with the finding by Käräjämäki et al [27]. However, Käräjämäki et al, observed from their data that,
10 in the absence of MS, fatty liver does not tend to pose a higher risk for development of T2D in
11 comparison to healthy subjects [27]. Our finding that, compared with healthy subjects (persons
12 with normal FLI and no MS), persons having high FLI and negative MS status were at increased
13 risk, disagrees with their observation.

14 Comparison of risks with FLI<10 as the reference reveals steady increase in risk across FLI (Figure
15 1). This supports the suggestion that, even among subjects with intermediate FLI, the risk of
16 incident T2D increases with increasing FLI values.

17 Our findings can be explained in the light of current knowledge. It is thought that an initial
18 development of insulin resistance results in compensatory hyperinsulinemia and, together with
19 visceral obesity, promotes the development of FLD [28]. In return, the insulin resistant fatty liver
20 overproduces glucose and VLDL. This boosts mechanisms that lead to exhaustion of pancreatic
21 beta cell reserve, eventually leading to the development of T2D [28]. Steatotic and inflamed liver
22 secretes hepatokines such as fetuin-A, fetuin-B, angiopoietin-like proteins, fibroblast growth factor
23 21, and selenoprotein P, that have endocrine function at extrahepatic sites to cause insulin

1
2
3 1 resistance and other adverse effects on glucose homeostasis [29]. Hence, the association of high
4
5 2 FLI with T2D.

6
7 3 Our finding that MS positive status is associated with higher risk than high FLI, and the co-
8
9 4 occurrence of MS with fatty liver is associated with the greatest risk, raises the suspicion that the
10
11 5 MS phenomenon represents a more advanced stage than FLD does, in the pathogenesis of T2D, as
12
13 6 proposed by Shibata et al [25], and suggested in recent epidemiological studies [27]. However, this
14
15 7 does not explain the population of persons with normal liver (low FLI) among people with MS.

16
17 8 The novel finding in our study is that although high FLI (FLD) is associated with increased risk
18
19 9 incident T2D, MS phenomenon, which may occur regardless of FLD, modifies this association.

20
21 10 However, the association is more clearly demonstrated when the reference group comprises of
22
23 11 subjects with normal liver and no MS. MS positive status can also predict T2D independent of FLI.

24
25 12 In addition, from our data, MS status is associated with higher risk than presence of fatty liver
26
27 13 (FLI \geq 60). However, FLI predicts T2D in subjects without MS. Although FLI appears to be a less
28
29 14 efficient predictor of T2D among subjects with MS, the co-presence of fatty liver and MS positive
30
31 15 status is associated with higher risk than that associated with MS alone. The reason why FLI did
32
33 16 not predict T2D among MS subjects is unclear. Our data revealed that among subjects with MS,
34
35 17 the association conferred by ggt and BMI (components variables of FLI that are not included in
36
37 18 MS), is not significant when compared with that conferred by insulin resistance and
38
39 19 hyperglycaemia. However, this finding of disparate association of FLD with T2D, by MS status,
40
41 20 needs to be studied further.

42
43 21 Our current study findings have clinical implications. Firstly, we show that FLI, a surrogate of
44
45 22 hepatic steatosis, predicts risk of incident T2D especially in persons who are negative for MS.

46
47 23 Secondly, the association can be affected by metabolic factors or MS status. This suggests that FLD

1
2
3 1 can also play a role in the pathogenesis of T2D. Therefore, both FLD and MS are useful for
4
5 2 screening risk of incident T2D.
6

7 3 Our study does have a number of limitations. Firstly, FLI as a surrogate of fatty liver does not
8
9 4 detect progression of FLD. Therefore, we are unable to differentiate the contribution of NASH and
10
11 5 fibrosis to the observed association. Another limitation of the study is that the hepatitis B and
12
13 6 hepatitis C statuses of the subjects were not established at baseline. The prevalence rate of
14
15 7 hepatitis B and hepatitis C, however, have remained low in the Finnish population (Karvonen
16
17 8 2016) (Safreed-Harmon 2018). Also, our study population comprised of men only. There are
18
19 9 reports that suggest that lower FLI cut off values may apply to women [30]. We are unable to
20
21 10 explore the influence of gender on the predictability of T2D using FLI. Nevertheless, Bedogni et al.,
22
23 11 concluded that the influence of gender in FLI is related to insulin and skinfold thickness, and
24
25 12 probably insignificant [7].
26
27
28
29

30 13 The strength of our study lies in the prospective design. With this, we are able to demonstrate the
31
32 14 ability of FLI, a surrogate of hepatic steatosis, to predict incident occurrence of T2D. We have also
33
34 15 adjusted for a range of constitutional factors, lifestyle factors and biomarkers keeping in
35
36 16 cognizance the components of both major exposure variables, to control for the possible
37
38 17 confounding factors in the predictability of T2D using FLI.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 1
4
5
6 2
7
8
9 3
10
11 4
12
13
14 5
15
16
17 6
18
19
20 7
21
22
23 8
24
25
26 9
27
28 10
29
30 11
31
32 12
33
34 13
35
36 14
37
38 15
39
40 16
41
42
43 17
44
45 18
46
47 19
48
49
50
51
52
53
54
55
56
57
58
59
60

CONCLUSION

In conclusion, our data show that high FLI category (FLD), is associated with increased risk of incident T2D, especially in subjects without MS. Persons with high FLI should be further evaluated for FLD and, if found with FLD, evaluated and monitored for T2D. FLD assessed using FLI can be used as additional screening tool for persons at increased risk of incident T2D in the general population. Both FLI and MS are useful, and can complement each other in screening and surveillance of persons at increased risk of T2D. In such persons, appropriate preventive or treatment measures should be instituted to improve their prognoses.

Competing interests:

The authors declare that they have no competing interests.

Authors' contributions:

1 OOO and T-PT conceived the study. OOO and T-PT designed the study. OOO performed the
2 statistical analyses. OOO wrote the first draft of the manuscript. JV , JP and T-PT contributed
3 towards development of this manuscript. All authors reviewed the final draft of the manuscript.

4 **Data sharing statement:**

5 No additional data are available.

6 **Acknowledgements:**

7 OOO received grants from the Finnish Cultural Foundation Central, Finland, in partial support for
8 the conduct of this study.

10 **REFERENCES**


- 11 1 Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver
12 disease—Meta-analytic assessment of prevalence, incidence, and outcomes, *Hepatology*
13 2016;64:73-84.
- 14 2 Kwon Y, Oh S, Hwang S, et al. Association of nonalcoholic fatty liver disease with components of
15 metabolic syndrome according to body mass index in Korean adults, *Am J Gastroenterol*
16 2012;107:1852.
- 17 3 Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus—
18 present and future perspectives, *Nature Reviews Endocrinology* 2012;8:228-36.
- 19 4 Perseghin G. The role of non-alcoholic fatty liver disease in cardiovascular disease, *Dig Dis*
20 2010;28:210-3.
- 21 5 Musso G, Gambino R, Cassader M, et al. Meta-analysis: natural history of non-alcoholic fatty liver
22 disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity, *Ann Med*
23 2011;43:617-49.
- 24 6 Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty
25 liver disease: Practice Guideline by the American Association for the Study of Liver Diseases,
26 American College of Gastroenterology, and the American Gastroenterological Association,
27 *Hepatology* 2012;55:2005-23.

- 1
2
3 1 7 Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of
4 2 hepatic steatosis in the general population, *BMC Gastroenterol* 2006;6:33.
5
6 3 8 Fedchuk L, Nascimbeni F, Pais R, et al. Performance and limitations of steatosis biomarkers in
7 4 patients with nonalcoholic fatty liver disease, *Aliment Pharmacol Ther* 2014;40:1209-22.
8
9 5 9 Jung C, Lee W, Hwang J, et al. Assessment of the fatty liver index as an indicator of hepatic
10 6 steatosis for predicting incident diabetes independently of insulin resistance in a Korean
11 7 population, *Diabetic Med* 2013;30:428-35.
12
13
14 8 10 Onat A, Can G, Kaya A, et al. Fatty liver disease: Disparate predictive ability for cardiometabolic
15 9 risk and all-cause mortality, *World J Gastroenterol* 2015;21:13555-65.
16
17 10 11 Salonen JT. Is there a continuing need for longitudinal epidemiologic research? The Kuopio
18 11 Ischaemic Heart Disease Risk Factor Study, *Ann Clin Res* 1988;20:46-50.
19
20 12 12 Salonen JT, Seppanen K, Nyyssonen K, et al. Intake of mercury from fish, lipid peroxidation, and
21 13 the risk of myocardial infarction and coronary, cardiovascular, and any death in eastern Finnish
22 14 men, *Circulation* 1995;91:645-55.
23
24 15 13 RÄSÄNEN J, Kauhanen J, Lakka T, et al. Religious affiliation and all-cause mortality: a
25 16 prospective population study in middle-aged men in eastern Finland, *Int J Epidemiol* 1996;25:1244-
26 17 9.
27
28 18 14 Laukkanen JA, Pukkala E, Rauramaa R, et al. Cardiorespiratory fitness, lifestyle factors and
29 19 cancer risk and mortality in Finnish men, *Eur J Cancer* 2010;46:355-63.
30
31 20 15 Willenbring ML, Massey SH, Gardner MB. Helping Patients Who Drink Too Much: An Evidence-
32 21 Based Guide for Primary Care Physicians. *Am Fam Physician* 2009;80.
33
34 22 16 McGuire S. U.S. Department of Agriculture and U.S. Department of Health and Human Services,
35 23 Dietary Guidelines for Americans, 2010. 7th Edition, Washington, DC: U.S. Government Printing
36 24 Office, January 2011, *Adv Nutr* 2011;2:293-4.
37
38 25 17 Fawehinmi TO, Ilomäki J, Voutilainen S, et al. Alcohol consumption and dietary patterns: the
39 26 FinDrink study, *PLoS One* 2012;7:e38607.
40
41 27 18 Virtanen JK, Mursu J, Tuomainen TP, et al. Dietary fatty acids and risk of coronary heart disease
42 28 in men: the Kuopio Ischemic Heart Disease Risk Factor Study, *Arterioscler Thromb Vasc Biol*
43 29 2014;34:2679-87.
44
45 30 19 Kauhanen J, Kaplan GA, Goldberg DE, et al. Pattern of alcohol drinking and progression of
46 31 atherosclerosis, *Arterioscler Thromb Vasc Biol* 1999;19:3001-6.
47
48 32 20 Alberti K. International Diabetes Federation Task Force on Epidemiology and Prevention;
49 33 National Heart, Lung, and Blood Institute; American Heart Association; Wo, *Circulation*
50 34 2009;120:1640-5.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 21 Cheema JR. Some general guidelines for choosing missing data handling methods in educational
4 2 research, *Journal of Modern Applied Statistical Methods* 2014;13:3.
5
6 3 22 Jäger S, Jacobs S, Kröger J, et al. Association between the fatty liver index and risk of type 2
7 4 diabetes in the EPIC-Potsdam Study, *PLoS one* 2015;10:e0124749.
8
9 5 23 Nishi T, Babazono A, Maeda T, et al. Evaluation of the fatty liver index as a predictor for the
10 6 development of diabetes among insurance beneficiaries with prediabetes, *Journal of diabetes*
11 7 *investigation* 2015;6:309-16.
12
13 8 24 Balkau B, Lange C, Vol S, et al. Nine-year incident diabetes is predicted by fatty liver indices: the
14 9 French D.E.S.I.R. study, *BMC Gastroenterol* 2010;10:56,230X-10-56.
15
16 10 25 Shibata M, Kihara Y, Taguchi M, et al. Nonalcoholic fatty liver disease is a risk factor for type 2
17 11 diabetes in middle-aged Japanese men, *Diabetes Care* 2007;30:2940-4.
18
19 12 26 Bedogni G, Bellentani S. Fatty liver: how frequent is it and why, *Ann Hepatol* 2004;3:63-5.
20
21 13 27 Karajamaki AJ, Bloigu R, Kauma H, et al. Non-alcoholic fatty liver disease with and without
22 14 metabolic syndrome: Different long-term outcomes, *Metabolism-Clinical and Experimental*
23 15 2017;66:55-63.
24
25 16 28 Valenti L, Bugianesi E, Pajvani U, et al. Nonalcoholic fatty liver disease: cause or consequence of
26 17 type 2 diabetes? *Liver International* 2016;36:1563-79.
27
28 18 29 Targher G, Byrne CD. Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for
29 19 type 2 diabetes and its complications, *The Journal of Clinical Endocrinology & Metabolism*
30 20 2013;98:483-95.
31
32 21 30 Yang BL, Wu WC, Fang KC, et al. External validation of fatty liver index for identifying
33 22 ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan, *PLoS One*
34 23 2015;10:e0120443.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Variation of hazard ratio of incident type 2 diabetes with baseline fatty liver index



STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1, 2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	2, 5
Methods			
Study design	4	Present key elements of study design early in the paper	6-8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	7, 9-10
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	9-10
		(c) Explain how missing data were addressed	9
		(d) If applicable, explain how loss to follow-up was addressed	8
		(e) Describe any sensitivity analyses	9-10
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	-
		(c) Consider use of a flow diagram	-
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	11, Table 1
		(b) Indicate number of participants with missing data for each variable of interest	7, 9
		(c) Summarise follow-up time (eg, average and total amount)	11
Outcome data	15*	Report numbers of outcome events or summary measures over time	11, Tables 2 & 3
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-11, Tables 2 & 3
		(b) Report category boundaries when continuous variables were categorized	9-11, Tables 2 & 3
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	12, Table 4, Figure 1
Discussion			
Key results	18	Summarise key results with reference to study objectives	14
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17
Generalisability	21	Discuss the generalisability (external validity) of the study results	17
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	19

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Association of Fatty Liver Index with risk of Incident Type 2 Diabetes by Metabolic Syndrome Status in an Eastern Finland Male Cohort

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026949.R1
Article Type:	Research
Date Submitted by the Author:	21-Mar-2019
Complete List of Authors:	Olubamwo, Olubunmi; Ita-Suomen yliopisto Terveystieteiden tiedekunta, Public Health and Clinical Nutrition Virtanen, Jyrki K.; Ita-Suomen yliopisto Kansanterveystiede ja kliininen ravitsemustiede, Public Health and Clinical Nutrition Pihlajämäki, Jussi; Public Health and Clinical Nutrition; Kuopio University Hospital, KYS , Clinical Nutrition and Obesity Center Tuomainen, Tomi-Pekka; Ita-Suomen yliopisto Kansanterveystiede ja kliininen ravitsemustiede, Public Health and Clinical Nutrition
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Gastroenterology and hepatology, Public health
Keywords:	EPIDEMIOLOGY, Hepatology < INTERNAL MEDICINE, Diabetes & endocrinology < INTERNAL MEDICINE, PREVENTIVE MEDICINE, PUBLIC HEALTH

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Association of Fatty Liver Index with risk of Incident Type 2 Diabetes by Metabolic Syndrome**
2 **Status in an Eastern Finland Male Cohort**

3 Olubunmi O. Olubamwo¹, Jyrki K. Virtanen¹, Jussi Pihlajamäki^{1,2}, Tomi-Pekka Tuomainen¹

4
5
6
7
8
9 ¹ Institute of Public Health and Clinical Nutrition, Faculty of Health Sciences, University of Eastern
10 Finland, Kuopio, Finland.

11 ² Clinical Nutrition and Obesity Center, Kuopio University Hospital, KYS Kuopio, Finland.
12
13
14
15
16
17

18
19
20
21 **Running head:** FLI and risk of T2D by MS status. Olubamwo et al.
22

23 **Word count:** main text 3897 words, abstract 288 words.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

*Corresponding author:

Olubunmi O, Olubamwo
Institute of Public Health and Clinical Nutrition
Faculty of Health Sciences
University of Eastern Finland, Kuopio,
P.O.Box 1627, FI-70211 Kuopio, Finland.
E-mail : olubunmi.olubamwo@uef.fi Tel : +358 403552905.

1 ABSTRACT

2 **Objective:** Fatty liver disease (FLD) is increasingly recognized as a predictor of cardiometabolic
3 risk. Our objective was to examine if metabolic syndrome (MS) status affects the association of
4 FLD with incident Type-2 diabetes (T2D) in middle-aged men.

5 **Design:** Prospective epidemiological study.

6 **Setting:** University affiliated research center in Kuopio, Eastern Finland.

7 **Participants:** our subjects were 1792 Finnish men without diabetes at baseline in the Kuopio
8 Ischaemic Heart Disease Risk Factor Study (KIHD) cohort.

9 **Outcome Measure:** Using fatty liver index (FLI), the association of baseline FLD with incident T2D
10 was analyzed in multivariable-adjusted Cox regression models, considering their MS statuses. The
11 main models were adjusted for constitutional factors, lifestyle factors, biomarkers of inflammation
12 and for high (FLI \geq 60) vs low (FLI $<$ 30) FLI categories.

13 **Results:** During a mean follow-up of 19 years, 375 incident cases of T2D were recorded. In the full
14 model, the hazard ratio (HR (95%CI)) for T2D was 3.68(2.80-4.82). The association was attenuated,
15 but maintained, with further adjustment for metabolic factors. When MS status was adjusted for in
16 place of metabolic factors, the HRs (95%CI) were 2.63(1.92-3.59) for FLI \geq 60 and 1.77(1.35-2.31) for
17 MS.

18 In MS-stratified analysis, FLI predicted T2D only among persons without MS. In unstratified analysis
19 with subjects categorized by FLI-MS, persons with FLI \geq 60 without MS had increased risk for T2D
20 (HR= 3.19(2.26-4.52)) compared with persons with FLI $<$ 30 without MS. Persons with FLI $<$ 30 and MS
21 had greater risk (HR= 4.31(2.15-8.61)) and, persons with both FLI \geq 60 and MS had the greatest risk
22 (HR=4.66(3.42-6.35)).

1
2
3 1 **Conclusion:** Generally, FLD (FLI \geq 60) predicts T2D. It specifically predicted T2D among men without
4
5 2 MS but not among men with MS, for whom MS alone already increases the risk. Both FLI and MS
6
7
8 3 can complement each other in screening and surveillance for persons with increased T2D risk.
9

10 4
11
12
13 5 **KEY WORDS:** fatty liver index, fatty liver disease, type 2 diabetes, metabolic syndrome, predictor,
14
15
16 6 metabolic factors, Kuopio Ischaemic Heart Disease Risk Factor Study
17
18
19 7

22 8 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- 25 9 • The study is population-based and the design is prospective, with long follow-up.
- 27 10 • We adjusted for a range of constitutional factors, lifestyle factors and biomarkers keeping
28
29 11 in cognizance the components of both major exposure variables to avoid overadjustment.
- 32 12 • The study population comprised of men only.
- 35 13 • Fatty Liver Index used as a surrogate of fatty liver does not detect progression of fatty liver
36
37 14 disease.
- 40 15 • The statuses of the men with respect to viral hepatitis were not established at baseline,
41
42 16 although, viral hepatitis have remained low in the Finnish population.

1 INTRODUCTION / BACKGROUND

2 There is increasing recognition of the fact that fatty liver disease (FLD) is the commonest cause of
3 chronic liver disease worldwide. Also known as hepatic steatosis, FLD is associated with increased
4 risk of cardiovascular disease (CVD) and Type 2 diabetes (T2D). The prevalence has been observed
5 to steadily rise; although, this varies in different populations. Recent estimates suggest a global
6 prevalence of 25% among adults, but the highest prevalence occurs in the Middle East and South
7 America while the lowest prevalence is in Africa [1]. The prevalence is estimated to be 24% in Europe
8 and more than 30% in developed countries [1]. Approximately one third of FLD patients progress to
9 steatohepatitis with fibrosis, which can thereafter progress to cirrhosis, liver failure and
10 hepatocellular carcinoma [1]. Fatty Liver Disease is intimately linked with metabolic diseases,
11 including T2D and, it can be considered a predictor of metabolic diseases, even in the non-obese
12 population [2].

13 While FLD is an acknowledged public health problem, there is growing interest in FLD as a predictor
14 of incident T2D [3]. A number of epidemiological studies suggest that non-alcoholic fatty liver
15 disease (NAFLD), diagnosed using either liver enzymes or ultrasound scan (USS), is associated with
16 an increase in T2D incidence [4, 5].

17 Liver biopsy is the gold standard for characterizing liver histology in patients with fatty liver. The
18 procedure is expensive and carries some morbidity and very rare mortality risks [6]. The fatty liver
19 index (FLI), an algorithm comprising of body mass index, waist circumference, gamma-glutamyl
20 transferase (GGT) and triglyceride concentrations. , It was developed by Bedogni et al., to predict
21 the presence of FLD. The algorithm has been widely validated, and has gained increased acceptance
22 [7, 8]. There have been reports of an association of high FLI (FLD) with incident T2D [9], [10].
23 However, with FLD being intimately linked with metabolic diseases, it is uncertain whether the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 predictive ability of FLD is independent of presence of established metabolic syndrome (MS), a
2 known potent predictor of T2D.
3 Therefore, using FLI as a surrogate for FLD, we examined whether MS status affects the association
4 of FLD, with incident T2D in middle-aged men.

For peer review only

1 METHODS

2
3
4
5
6 **Study population:** Our study population comprised participants in the Kuopio Ischaemic Heart
7
8 Disease Risk Factor Study (KIHD). The KIHD study is a prospective population-based study. It was
9
10 designed to investigate risk factors for CVDs and related outcomes, in middle-aged and ageing men,
11
12 from Eastern Finland. The original study population consisted of an age-stratified sample of 2682
13
14 men. These were enrolled at baseline between March 1984 and December 1989. The men were 42,
15
16 48, 54, or 60 years of age at baseline. The study was approved by the Research Ethics Committee of
17
18 the University of Kuopio [11], and the subjects gave their written consent.
19
20
21
22

23
24 **Data Collection:** Data were collected using self-administered questionnaires, interviews, physical
25
26 examinations, and various blood tests which aimed to elucidate physiological and biochemical
27
28 parameters [12, 13]. The self-administered questionnaire was used to collect data on medical
29
30 history, including history of type 2 diabetes, metabolic diseases, liver disease, etc., medication
31
32 history, family history of diabetes, and family history of CVD[12]. Data on lifestyle, including physical
33
34 activity, history of smoking habit, history of alcohol consumption, and diet, were also collected [14].
35
36 Categorisation of alcohol consumption was done according to standard guidelines by the National
37
38 Institute of Alcohol Abuse and Alcoholism [15] and Dietary Guidelines for Americans 2010 [16] as
39
40 already published [17].
41
42
43
44
45

46 A family history of CVD or diabetes was defined as positive if the father, mother, sister, or brother
47
48 of the subject had a history of CVD or diabetes. [12]. A subject was defined as a smoker if he had
49
50 ever smoked on a regular basis and had smoked cigarettes, cigars, or pipe within the previous 30
51
52 days. Dietary intakes including fruit, berry and vegetable consumption were assessed with a 4-day
53
54 food recording [18].
55
56
57
58
59
60

1
2
3 1 Physical examinations included anthropometric indices, vital signs, and physiologic measurements.
4
5 2 All measurements were made following standard protocols. Waist circumference was calculated as
6
7
8 3 the mean of waist circumferences taken at maximal inspiration and maximal expiration. Body mass
9
10 4 index (BMI) was computed as the ratio of weight in Kg to the square of height in meters (kg/m²).
11
12
13 5 Blood pressure, was taken as the mean of measurements taken in the supine, standing and sitting
14
15 6 position with 5-minute intervals [19].
16
17

18 7 **Specimen collection and laboratory measurements-** Blood samples were collected between 08.00
19
20 8 and 10.00 hours after 3 days of abstinence from alcohol ingestion and a 12-hour abstinence from
21
22
23 9 smoking and eating. Data on complete blood count, serum electrolytes, Homeostatic model
24
25 10 assessment of insulin resistance (HOMA1-IR), fasting glucose, lipoprotein fractions (including total
26
27 11 cholesterol, HDL cholesterol, LDL cholesterol, serum triglycerides), liver function tests including
28
29 12 albumin, gamma-glutamyl transferase, fibrinogen, ferritin, and biomarkers like C-reactive protein
30
31 13 (CRP), were each determined from appropriately collected and processed samples. Detailed
32
33 14 description of the KIHD has been published elsewhere [11].
34
35
36
37

38 15 **Included and excluded subjects:** The initial number of men at baseline was 2682. Of these, we
39
40 16 excluded 40 men with history of physician diagnosed liver or pancreas disease, and 162 men with
41
42 17 history of diabetes. Of the remaining 2480 men, 1792 who had complete data for FLI calculation,
43
44 18 were included in the analyses.
45
46
47

48 19 **Measuring the components of the Fatty liver index:** We calculated FLI using the algorithm
49
50 20 developed by Bedogni et al [7]. The algorithm, incorporates four variables: BMI, waist
51
52 21 circumference, serum triglycerides, and serum gamma-glutamyl transferase (GGT), and is expressed
53
54 22 as follows:
55
56
57
58
59
60

$$FLI = \frac{(e^{0.953 \times \ln(\text{triglycerides}) + 0.139 \times \text{BMI} + 0.718 \times \ln(\text{ggT}) + 0.053 \times \text{waist circumference} - 15.745})}{(1 + e^{0.953 \times \ln(\text{triglycerides}) + 0.139 \times \text{BMI} + 0.718 \times \ln(\text{ggT}) + 0.053 \times \text{waist circumference} - 15.745})} \times 100$$

Where triglycerides is in mg/dl, waist circumference in cm, and BMI in Kg/m². We categorized FLI in accordance with Bedogni's categorization, as low FLI (<30), intermediate FLI (30-<60), and moderate-high FLI (>60), indicating no fatty liver, indeterminate, and fatty liver, respectively.

Defining Metabolic Syndrome Status: MS was defined in accordance with the harmonized criteria for diagnosis of MS [20]. The presence of any three of the following five risk factors constitutes a diagnosis of metabolic syndrome: waist circumference ≥ 120 cm; serum triglycerides ≥ 150 mg/dL (1.7 mmol/L) (or drug treatment for elevated triglycerides); HDL cholesterol < 40 mg/dL (1.0 mmol/L) (or drug treatment for reduced HDL cholesterol); blood pressure with systolic ≥ 130 and/or diastolic ≥ 85 mm Hg (or antihypertensive drug treatment in a patient with a history of hypertension); fasting glucose ≥ 100 mg/dl (or drug treatment of elevated glucose), [20].

Outcome Definitions: We defined incident T2D outcomes as self-reported physician-set diagnosis of T2D and/or; fasting plasma glucose ≥ 7.0 mmol/L or 2-h oral glucose tolerance test plasma glucose ≥ 11.1 mmol/L at re-examination rounds 4, 11, and 20 years after the baseline and; T2D information derived by record linkage to either the national hospital discharge registers or to the Social Insurance Institution of Finland register for reimbursement of medicine expenses used for T2D. Detection of T2D by self-report of physician diagnosed T2D was followed by either detection via the hospital discharge registers or National drug reimbursement register. The proportion of the data obtained by the record linkage are as follows: hospital discharge registers 42%, and National drug reimbursement register 58%. T2D cases that were included were those coded in the Tenth International Classification of Diseases (ICD 10 code numbers from E11.0 to E11.9).

1
2
3 1 **Patient and public involvement:** The study was carried out in a non-patient research facility. All the
4
5
6 2 study participants were volunteers. Neither the study participants nor the public were involved in
7
8 3 the design of the study.
9

10
11 4
12
13 5 **Statistical Methods:** All statistical analyses were performed using SPSS software Version 21.0 for
14
15
16 6 Windows (IBM, Chicago, IL). In all analyses, two-sided alpha <0.05 was considered statistically
17
18 7 significant.
19

20
21 8 Descriptive analyses were performed to summarise baseline characteristics of participants
22
23 9 according to baseline FLI categories. For continuous variables, we used Jonckheere trend test to test
24
25
26 10 for linear trend across FLI categories. For categorical variables, we used Chi-Square test to test for
27
28 11 linear association across FLI categories. To make up for missing 0.4% values (spread across 50% of
29
30
31 12 the variables and 13.4% of subjects), we used a regression based multiple imputation method (40
32
33 13 iterations) according to guideline by Cheema 2014 [21].
34
35

36 14 After confirmation of proportionality of hazards, we implemented a multivariable-adjusted Cox
37
38
39 15 proportional hazards model, to examine the relationship between baseline FLI and incident T2D
40
41 16 considering metabolic factors and the MS statuses of the subjects as follows:
42
43

44 17 First, we analyzed the overall association, adjusting for MS status. The models were as follows:
45
46
47 18 model 1- Examination year, constitutional factors (age and family history of T2D), lifestyle factors
48
49 19 (smoking pack years, alcohol consumption, physical activity and, consumption of fruits, berries and
50
51 20 vegetables) and, inflammatory markers (C-reactive protein, leukocyte count, thrombocyte count),
52
53
54 21 and metabolic factors (fasting glucose, insulin, HDL, LDL, systolic blood pressure, diastolic blood
55
56 22 pressure); model 2- Examination year, constitutional factors (age and family history of T2D), lifestyle
57
58
59 23 factors (smoking pack years, alcohol consumption, physical activity and, consumption of fruits,
60

1
2
3 1 berries and vegetables) and, inflammatory markers (C-reactive protein, leukocyte count,
4
5
6 2 thrombocyte count), and MS status.

7
8
9 3 In sensitivity analyses, we excluded men with a high weekly alcohol consumption of ≥ 168 g [17]
10
11 4 before analyzing the overall association of FLI with T2D in multivariable adjusted Cox proportional
12
13 5 hazards as explained above. In addition, we excluded smokers before analyzing the overall
14
15
16 6 association of FLI with T2D in multivariable adjusted Cox proportional hazards.

17
18
19 7 Secondly, we performed sub-group analyses in which we stratified our study sample by MS status.
20
21 8 We then performed multivariable-adjusted Cox proportional hazards analysis with adjustment for
22
23 9 covariates to observe if the association of FLI with incident T2D differs by MS status in model 1 and
24
25
26 10 2 as explained above, but excluding fasting glucose in model 2.

27
28
29 11 Thirdly, for clearer understanding of the relation of the associations considering both FL and MS
30
31 12 statuses, using the combination of FLI category and MS status as a composite variable, we
32
33 13 performed multivariable-adjusted Cox proportional hazards analysis on the study population with
34
35
36 14 adjustment for covariates as in model 1 above, to elaborate the variation of the association by MS
37
38
39 15 status.

1 RESULTS

2
3
4
5
6 2 **Characteristics of the study population:** The baseline characteristics of the study population (1792
7
8
9 3 men) according to FLI categories are shown in Table 1. In general, the mean values and proportions
10
11 4 for men in the intermediate FLI category were in between estimates for the lowest (reference) FLI
12
13
14 5 category and estimates for the highest FLI category. Compared with the low FLI category, the high
15
16 6 FLI category had a greater proportion of men with family history of diabetes, and a greater
17
18
19 7 proportion with family history of CVD. Men in the high FLI category consumed less fruit, berries and
20
21 8 vegetables, and more likely to be heavy alcohol consumers. They had higher mean waist
22
23
24 9 circumference and mean BMI and they were more likely to be hypertensive. They also had higher
25
26 10 GGT levels, higher triglyceride, higher fasting insulin, higher blood glucose, lower HDL cholesterol
27
28
29 11 and higher levels of markers of systemic inflammation. Generally, the range of values of the fasting
30
31 12 blood glucose for the eligible men was between 3.1 mmol/l (minimum) and 6,2 mmol/l (or
32
33 13 112mg/dl) (maximum).

34
35
36 14 **Multivariable proportional hazards model analyses:** During a mean (SD) follow-up of 18.8(6.6)
37
38
39 15 years, there were 375 cases of incident T2D. The incidence rates for T2D were 11 cases per 1000
40
41 16 person-years. Significantly lower survival free of incident T2D was noted for participants in high
42
43
44 17 baseline FLI category compared to the low (normal) FLI category at baseline (Log-rank < 0.001).
45
46 18 Subjects in intermediate FLI category also separated clearly from those with Low FLI for incident
47
48
49 19 T2D.

20 **Relation between baseline Fatty Liver Index and incident T2D**

51
52
53
54 21 **Overall analyses:** Table 2 shows the association of FLI with incident T2D. In model 1, the HRs for
55
56
57 22 incident T2D was 42% higher for the intermediate category, and 113% higher for the high FLI
58
59 23 category, when compared with the low category. The association was maintained, in model 2 with
60

1 MS where high FLI category was associated with 163% increased risk. MS was also independently
2 associated with incident T2D in the model, with 77% increased risk (HR (95%CI) 1.77(1.35-2.31)).

3 *Sensitivity analyses* - after exclusion of 241 men who were heavy alcohol consumers (Table 3), the
4 results were similar to those obtained in the analyses with the whole sample, as shown in Table 2.

5 Similarly, after exclusion of 571 men who were smokers (Appendix), the results were similar to those
6 obtained in the analyses with the whole sample, as shown in Table 1 of the appendix.

7 Further exploration of the association of FLI with incident T2D across FLI categories of 10 (see Figure
8 1) reveals steady increase in HR across the categories without any threshold areas. When we
9 analyzed our data with FLI as continuous variable, a unit increase in FLI was associated with 1.7%
10 increase in HR (in the analyses with the whole sample), and 1.8% increase (after exclusion heavy
11 alcohol consumers), as shown in Tables 2 and 3.

12 **Stratified analyses:** Table 4 shows the results of Cox regression analysis when we stratified by MS
13 status. In the stratus without MS, high FLI was associated with over 100% increased risk of T2D when
14 compared with those in the low FLI category. Among those with MS, high FLI was not associated
15 with additional risk when compared with those in the low FLI category.

16 **Analysis with composite FLI-MS variable:** In additional sensitivity analyses, with the combination of
17 FLI category and MS status as composite exposure variable, when compared with subjects having
18 neither fatty liver nor MS, having high FLI with no MS was associated with 219% increase in risk (the
19 HR (95%CI) was 3.19(2.26-4.51)). Having normal FLI with MS was associated with 331% increased
20 risk (the HR (95%CI) was 4.31(2.15-8.61)) and, persons having high FLI and MS were at greatest risk,
21 with 366% increase in risk (HR (95%CI) 4.66(3.42-6.35)). The presence of MS was associated with
22 greater risk in intermediate and high FLI categories (the HRs (95%CI) were 3.77(2.50-5.70) for
23 presence of MS with intermediate FLI category, and 4.66(3.42-6.35) for the presence of MS with
24 high FLI category).

1 **Table 1 - Baseline characteristics of 1792 men according to fatty liver index (FLI) categories**

Characteristic	FLI<30	FLI=30-< 60	FLI≥60	P-trend*
	Mean (SD)	Mean (SD)	Mean (SD)	
	or n (%)	or n (%)	or n (%)	
	N=833	N=552	N=407	
FLI	16.2 (7.7)	43.3 (8.1)	76.8 (10.6)	<0.001
Constitutional factors				
Age in years	52.6 (5.6)	53.4 (5.5)	52.5 (5.6)	0.251
Family history of diabetes	212 (25.5%)	145 (27.8%)	108 (26.5%)	0.651
Family history of CVD	667 (80.1%)	459 (83.2%)	341 (83.8%)	0.072
Lifestyle factors				
Smoking pack years	7.5(16.0)	8.4(16.8)	6.8(13.6)	0.785
Alcohol consumption (g/week)	55 (89)	78 (117)	116 (165)	<0.001
Physical activity (Energy exp.) (kcal/day)	136(156)	147(175)	129(192)	0.36
Fruit, berry and vegetable consumption (g/day)	265 (171)	261 (148)	233 (147)	0.023
Anthropometrics and physiologic measurements				

Mean waist circumference (cm)	83.9 (6.1)	92.7 (5.2)	101.8 (8.1)	<0.001
BMI (kg/m ²)	24.4 (2.0)	27.3 (1.9)	30.7 (3.1)	<0.001
Mean systolic bp	135.5(17.0)	135.7(17.8)	135.9(18.1)	<0.001
Mean diastolic bp	89.4(10.5)	88.5(10.6)	89.6(11.1)	<0.001
Hypertension	259 (31.1%)	275 (49.8%)	261 (64.1%)	<0.001
Biomarkers				
Insulin	8.3 (3.0)	11.2 (4.4)	16.6 (9.7)	<0.001
Glucose (mmol/L)	4.5 (0.4)	4.6 (0.5)	4.8 (0.5)	<0.001
HOMA1-IR insulin resistance	1.86 (0.71)	2.60 (1.10)	3.91 (2.30)	<0.001
Total cholesterol (mmol/L)	5.71 (1.07)	5.93 (1.02)	6.05 (1.00)	<0.001
HDL cholesterol (mmol/L)	1.38 (0.32)	1.25 (0.26)	1.20 (0.27)	<0.001
LDL cholesterol (mmol/L)	3.91 (1.01)	4.09 (0.97)	4.01 (0.93)	0.04
Triglycerides (mmol/L)	0.94 (0.40)	1.35 (0.62)	1.93 (1.02)	<0.001
Gamma-glutamyl transferase (U/L)	18 (11)	28 (20)	51 (47)	<0.001
Albumin	42 (4)	42 (4)	43 (3)	<0.001
C- reactive protein (m/L)	1.86 (4.46)	2.61 (4.54)	3.15 (4.26)	<0.001
Ferritin (µg/L)	128 (100)	172 (157)	235 (186)	<0.001

Fibrinogen g/L	2.92 (0.58)	3.06 (0.57)	3.10 (0.55)	<0.001
Leukocyte count x10 ⁹ /L	5.4 (1.6)	5.7 (1.6)	5.9 (1.6)	<0.001
Metabolic syndrome and medication use history				
Metabolic syndrome	29 (3.5%)	91 (16.5%)	238 (58.5%)	<0.001
Drug for high cholesterol	7 (0.84%)	2 (0.36%)	6 (1.47%)	0.509
Drug for hypertension	111 (13.32%)	127 (23.05%)	141(34.56%)	<0.001

*Jonckheere trend test for continuous variable. Chi-Square linear-by-linear association for categorical variables. bp-
blood pressure

1 DIABETES PREDICTION

2 **Table 2 – General association of baseline fatty liver index (FLI) with incident type 2 diabetes**

FLI	Number of subjects (%) with T2D (IR)	Model 1 HR (95% CI)	Model 2 HR (95% CI)
FLI*	1792 (20.9) (11)	1.013(1.007-1.018) ^a	1.017(1.012-1.022) ^b
FLI category			
≤30 (Ref.)	833 (12.1) (6)	1.000	1.000
30-<60	552 (22.6) (12)	1.42(1.07-1.88)	1.81(1.38-2.37)
≥60	407 (36.6) (22)	2.13(1.56-2.93) ^a	2.63(1.92-3.59) ^b
P-trend	-	<0.001	<0.001

3 *FLI uncategorized, HR – hazard ratio. CI – confidence interval. T2D – type 2 diabetes, IR – Incidence rate per 1000 person-years

4 Model 1: FLI, age, examination date, family history of diabetes, smoking pack years, alcohol consumption per week, physical activity, fruit-berry-vegetable consumption, C-reactive protein, leukocytes albumin, fibrinogen, and ferritin, systolic blood pressure, diastolic blood pressure, insulin, fasting glucose, LDL, and HDL.

5 Model 2: FLI, age, examination date, family history of diabetes, smoking pack years, alcohol consumption per week, physical activity, fruit-berry-vegetable consumption, C-reactive protein, leukocytes albumin, fibrinogen, and ferritin, and metabolic syndrome status.

6 ^a Other independent predictors of T2D in the model were family history of diabetes, serum ferritin, hypertension, serum insulin, and glucose.

7 ^b Other independent predictors of T2D in the model were family history of diabetes, serum ferritin and metabolic syndrome status. HR metabolic syndrome = 1.77(1.35-2.31).

Table 3 – Association of baseline fatty liver index with incident type 2 diabetes after excluding men with high alcohol intake

FLI	Number of subjects (% with T2D) (IR)	Model 1 HR (95% CI)	Model 2 HR (95% CI)
FLI*	1548(20.9) (11)	1.014(1.008-1.019)	1.018(1.012-1.024)
FLI category			
≤30 (Ref.)	771(12.5) (6)	1.000	1.000
30-<60	472(23.1) (12)	1.43(1.06-1.93)	1.78(1.33-2.37)
≥60	305(38.7) (23)	2.21(1.57-3.10)	2.63(1.89-3.66)
P-trend	-	<0.001	<0.001

FLI – fatty liver index, FLI* - FLI uncategorized, HR – hazard ratio. CI – confidence interval. T2D – type 2 diabetes, IR – Incidence rate per 1000 person-years

Model 1: FLI, age, examination date, family history of diabetes, smoking pack years, alcohol consumption per week, physical activity, fruit-berry-vegetable consumption, C-reactive protein, leukocytes albumin, fibrinogen, and ferritin, systolic blood pressure, diastolic blood pressure, insulin, fasting glucose, LDL, and HDL.

Model 2: FLI, age, examination date, family history of diabetes, smoking pack years, alcohol consumption per week, physical activity, fruit-berry-vegetable consumption, C-reactive protein, leukocytes albumin, fibrinogen, and ferritin, and metabolic syndrome status.^a Other independent predictors of T2D in the model were family history of diabetes, serum ferritin, hypertension, serum insulin, and fasting glucose.

^b Other independent predictors of T2D in the model were family history of diabetes, serum ferritin and metabolic syndrome status. HR metabolic syndrome = 1.65(1.24-2.21).

1
2
3 **Table 4 – Association of fatty liver index (FLI) with incident type 2 diabetes by metabolic**
4 **syndrome status (sub-analyses)**
5

No metabolic syndrome	Number of subjects (% with T2D) (IR)	Model 1 HR(95%CI)	Model 2 HR(95%CI)
FLI*	1427(16.7) (9)	1.021 (1.015-1.027)	1.017 (1.010-1.025) ^a
FLI category			
≤30 (Ref.)	803(11.5) (6)	1.00	1.00 ^b
30-<60	456(20.0) (11)	1.81(1.33-2.46)	1.58(1.14-2.19)
≥60	168(33.3) (18)	3.07(2.14-4.41)	2.38(1.58-3.58)
p-trend		<0.001	<0.001
Metabolic syndrome	Number of subjects (% with T2D) (IR)	Model 1 HR(95%CI)	Model 2 HR(95%CI)
FLI*	358(37.7)(24)	1.007(0.997-1.016)	0.996(0.992-1.000) ^c
FLI category			
≤30 (Ref.)	29(31.0) (23)	1.000	1.000 ^d
30-<60	91(36.3) (21)	0.77(0.35-1.70)	0.80(0.59-1.09)
≥60	238(39.1) (25)	1.02(0.49-2.16)	0.79 (0.58-1.06)
p-trend		0.42	0.22
Category by FLI and MS status	Number of subjects (% with T2D) (IR)	Model 1 HR(95%CI)	
FLI≤30 MS ⁻	803(11.5) (6)	1.000	-
FLI30-<60MS ⁻	456(20.0) (11)	1.79(1.33-2.41)	-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FLI \geq 60MS ⁻	168(33.3) (18)	3.19(2.26-4.51)	-
FLI \leq 30 MS ⁺	29(31.0) (23)	4.31(2.15-8.61)	-
FLI30-<60MS ⁺	91(36.3) (21)	3.77(2.50-5.70)	-
FLI \geq 60MS ⁺	238(39.1) (25)	4.66(3.42-6.35)	-

*FLI uncategorized, Ref – reference. HR – hazard ratio. CI – confidence interval. T2D – type 2 diabetes, IR – Incidence rate per 1000 person-years

*Statistically significant at $P \leq 0.05$. MS – Metabolic syndrome. MS⁻ - Metabolic syndrome negative. MS⁺ - Metabolic syndrome positive.

Model 1: FLI, age, examination date, family history of diabetes, smoking pack years, alcohol consumption per week, physical activity, fruit-berry-vegetable consumption, C-reactive protein, leukocytes, thrombocytes, fibrinogen, and ferritin.

Model 2: Model 1 plus systolic blood pressure, diastolic blood pressure, insulin, LDL, and HDL

^a Other independent predictors of T2D in the model were serum ferritin and insulin.

^b Other independent predictors of T2D in the model were serum ferritin and insulin.

^c Independent predictors of T2D in the model were fasting glucose and insulin.

^d Independent predictors of T2D in the model were fasting glucose and insulin.

Figure 1 – Graph of FLI and risk of incident T2D.

1 DISCUSSION

2 We examined the association of FLI, a surrogate of fatty liver disease, in relation to incident T2D in
3 a population of middle-aged men, while taking the baseline MS status into account. We found that
4 although FLD assessed by FLI predicts the risk of T2D in the study population, the association was
5 strongest among persons without MS at baseline.

6 Few studies have investigated the association of baseline FLI as categorized by Bedogni et al., with
7 incident T2D [10, 22]. Jager et al.[22] and Onat et al. [10], studied the association of FLI with incident
8 T2D in healthy populations, followed up for eight years. Nishi et al.[23], studied the association of
9 FLI with incident T2D in a population of prediabetic subjects followed up for three years[23].

10 A few studies, Balkau et al.[24] and Jung et al.[9] also reported the association of FLI with incident
11 T2D using FLI categorization different from that proposed by Bedogni et al. [9, 24]. Because previous
12 studies on the association of FLI with incident T2D have adjusted for different groups of variables in
13 their multivariable models, we are careful in our comparison of findings.

14 Our finding that high FLI (FLI \geq 60) indicating fatty liver, is associated with increased risk independent
15 of constitutional and lifestyle factors, agrees with findings from previous findings by Jager et al.[22]
16 and Onat et al.[10]. We found a 2 to 3-fold increased risk in our multivariable adjusted models.
17 However, Jager et al., reported 11-fold increase while Onat et al reported a 5-fold increase. Our
18 finding, that intermediate FLI is also associated with increased risk of T2D, is also in line with reports
19 by Jager et al.

20 Our finding that high FLI is associated with incident T2D even after adjusting for metabolic factors,
21 agrees with other reports.[10],[24] [9], each of which used different cut-off points in categorizing
22 FLI. Balkau et al. used FLI <20 and FLI \geq 70 as lower and upper cut-off points, and adjusted for glucose,
23 insulin, and hypertension. Jung et al, used FLI<20 and FLI \geq 60 as lower and upper cut-off points.

1
2
3 1 When we re-analyzed our data using these cut-off points, the results (data not shown) did not differ
4
5 2 markedly from what we present here.
6
7

8
9 3 Indeed, ultrasound diagnosed NAFLD has been shown to be associated with incident T2D and, the
10
11 4 association is not affected by adjustment for metabolic syndrome [5]. However, the predictability
12
13 5 of T2D independent of MS using FLI needs to be clarified.
14
15

16 6 We are unable to compare our findings on association of FLI with incident T2D in view of MS status
17
18 7 of the subjects, with previous studies on the association between FLI and incident T2D because
19
20 8 previous studies on the association did not consider the MS status of the subjects. However, this
21
22 9 finding corroborates the report by Shibata et al. [25]. Shibata et al. found that the presence of fatty
23
24 10 liver, as diagnosed by ultrasonography, is associated with increased risk of T2D when compared with
25
26 11 those without fatty liver after adjusting for age, BMI, smoking status, physical activity, and MS status
27
28 12 [25].
29
30
31
32

33 13 The finding of similar results, after excluding men who were heavy consumers of alcohol, indicates
34
35 14 that our findings are also applicable to NAFLD. However, despite the multifactorial nature of the
36
37 15 aetiology of FLD, the relative contribution of heavy ethanol intake in the pathogenesis of fatty liver
38
39 16 is still uncertain [26]. Therefore, we did not exclude men with high alcohol intake in our main
40
41 17 analysis. The finding of similar results after excluding smokers proves further that smoking is not a
42
43 18 confounder in this target population.
44
45
46
47

48 19 It is remarkable that, stratification by MS status did not reveal significant association of high FLI with
49
50 20 incident T2D in subjects with MS, despite the fact that increasing proportions of subjects with MS
51
52 21 developed T2D across the FLI categories. This suggests that among persons with MS, which is already
53
54 22 a cluster of risk factors for T2D (including hyperglycaemia), high FLI is likely not associated with
55
56 23 significantly higher risk than that due to positive MS status alone. It also suggests that the MS status
57
58 24 was an effect modifier in the overall analysis.
59
60

1
2
3 1 Notwithstanding, our findings from the analysis with FLI-MS composite variable, are noteworthy. It
4
5
6 2 appears that FLI predicts risk of T2D in a dose-dependent manner among subjects without MS but
7
8 3 among subjects with MS, it does not predict risk of T2D in a dose-dependent manner. The additional
9
10 4 risk associated with high FLI appears less than that associated with MS positive status. Therefore,
11
12
13 5 the greatest risk was in subjects with both fatty liver and MS positivity. Our finding that the presence
14
15 6 of MS appears to be associated with higher risks than high FLI, may be consistent with the finding
16
17
18 7 by Käräjämäki et al [27]. However, Käräjämäki et al, observed from their data that, in the absence
19
20 8 of MS, fatty liver does not tend to pose a higher risk for development of T2D in comparison to
21
22
23 9 healthy subjects [27]. Our finding that, compared with healthy subjects (persons with normal FLI
24
25 10 and no MS), persons having high FLI and negative MS status were at increased risk, disagrees with
26
27
28 11 their observation.

29
30 12 Comparison of risks with FLI<10 as the reference reveals steady increase in risk across FLI (Figure 1).
31
32
33 13 This supports the suggestion that, even among subjects with intermediate FLI, the risk of incident
34
35 14 T2D increases with increasing FLI values.

36
37 15 Our findings can be explained in the light of current knowledge. It is thought that an initial
38
39
40 16 development of insulin resistance results in compensatory hyperinsulinemia and, together with
41
42 17 visceral obesity, promotes the development of FLD [28]. In return, the insulin resistant fatty liver
43
44
45 18 overproduces glucose and very low-density lipoprotein. This boosts mechanisms that lead to
46
47 19 exhaustion of pancreatic beta cell reserve, eventually leading to the development of T2D [28].
48
49
50 20 Steatotic and inflamed liver secretes hepatokines such as fetuin-A, fetuin-B, angiotensin-like
51
52 21 proteins, fibroblast growth factor 21, and selenoprotein P, that have endocrine function at
53
54
55 22 extrahepatic sites to cause insulin resistance and other adverse effects on glucose homeostasis [29].
56
57 23 Hence, the association of high FLI with T2D.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Our finding that MS positive status is associated with higher risk than high FLI, and the co-occurrence
2 of MS with fatty liver is associated with the greatest risk, raises the suspicion that the MS
3 phenomenon represents a more advanced stage than FLD does, in the pathogenesis of T2D, as
4 proposed by Shibata et al [25], and suggested in recent epidemiological studies [27]. However, this
5 does not explain the population of persons with normal liver (low FLI) among people with MS.

6 The novel finding in our study is that although high FLI (FLD) is associated with increased risk incident
7 T2D, MS phenomenon, which may occur regardless of FLD, modifies this association. However, the
8 association is more clearly demonstrated when the reference group comprises of subjects with
9 normal liver and no MS. MS positive status can also predict T2D independent of FLI. In addition,
10 from our data, MS status is associated with higher risk than presence of fatty liver ($FLI \geq 60$). However,
11 FLI predicts T2D in subjects without MS. Although FLI appears to be a less efficient predictor of T2D
12 among subjects with MS, the co-presence of fatty liver and MS positive status is associated with
13 higher risk than that associated with MS alone. The reason why FLI did not predict T2D among MS
14 subjects is unclear. Our data revealed that among subjects with MS, the association conferred by
15 ggt and BMI (components variables of FLI that are not included in MS), is not significant when
16 compared with that conferred by insulin resistance and hyperglycaemia. However, this finding of
17 disparate association of FLD with T2D, by MS status, needs to be studied further.

18 Our current study findings have clinical implications. Firstly, we show that FLI, a surrogate of hepatic
19 steatosis, predicts risk of incident T2D especially in persons who are negative for MS. Secondly, the
20 association can be affected by metabolic factors or MS status. This suggests that FLD can also play
21 a role in the pathogenesis of T2D. Therefore, both FLD and MS are useful for screening risk of
22 incident T2D. From health systems perspective, because high FLI has also been associated with
23 increased risk of CVD [30], and it appears to be detectable before MS may be apparent, screening

1
2
3 1 with FLI may be more cost effective in asymptomatic persons. The finding of FLI in high category
4
5
6 2 should then prompt further evaluation for T2D and CVD.
7

8 3 Our study does have a number of limitations. Firstly, FLI as a surrogate of fatty liver does not detect
9
10 4 progression of FLD. Therefore, we are unable to differentiate the contribution of NASH and fibrosis
11
12
13 5 to the observed association. Another limitation of the study is that the hepatitis B and hepatitis C
14
15 6 statuses of the subjects were not established at baseline. The prevalence rate of hepatitis B and
16
17
18 7 hepatitis C, however, have remained low in the Finnish population (Karvonen 2016) (Safreed-
19
20 8 Harmon 2018). Also, our study population comprised of men only. There are reports that suggest
21
22
23 9 that lower FLI cut off values may apply to women [31]. We are unable to explore the influence of
24
25 10 gender on the predictability of T2D using FLI. Nevertheless, Bedogni et al., concluded that the
26
27
28 11 influence of gender in FLI is related to insulin and skinfold thickness, and probably insignificant [7].
29
30 12 The strength of our study lies in the prospective design. With this, we are able to demonstrate the
31
32
33 13 ability of FLI, a surrogate of hepatic steatosis, to predict incident occurrence of T2D. We have also
34
35 14 adjusted for a range of constitutional factors, lifestyle factors and biomarkers keeping in cognizance
36
37
38 15 the components of both major exposure variables, to control for the possible confounding factors
39
40 16 in the predictability of T2D using FLI.
41
42

43 17
44
45

46 18
47
48

49 19
50
51

52 20
53
54

55 21
56
57

58 22
59
60

1 2 3 1 **CONCLUSION**

4
5
6 2 In conclusion, our data show that high FLI category (FLD), is associated with increased risk of incident
7
8 3 T2D, especially in men without MS. Persons with high FLI should be further evaluated for FLD and,
9
10 4 if FLD is present, they should be evaluated and monitored for T2D. FLD assessed using FLI can be
11
12 5 used as additional screening tool for persons at increased risk of incident T2D in the general
13
14 6 population. Both FLI and MS are useful, and can complement each other in screening and
15
16 7 surveillance of persons at increased risk of T2D. In such persons, appropriate preventive or
17
18 8 treatment measures should be instituted to improve their prognoses.
19
20
21
22

23 9 24 25 10 **Competing interests:**

26
27
28
29 11 The authors declare that they have no competing interests.
30
31

32 12 **Authors' contributions:**

33
34
35 13 OOO and T-PT conceived the study. OOO and T-PT designed the study. OOO performed the
36
37 14 statistical analyses. OOO wrote the first draft of the manuscript. JV , JP and T-PT contributed towards
38
39 15 development of this manuscript. All authors reviewed the final draft of the manuscript.
40
41
42

43 16 **Data sharing statement:**

44
45
46 17 No additional data are available.
47
48

49 18 **Acknowledgements:**

50
51
52 19 OOO received study grant from the Finnish Cultural Foundation Central, Finland (Suomen
53
54 20 Kulttuurirahasto), in partial support for the conduct of this study.
55
56

57
58 21 Language editing was by Enembe O Okokon MBBch., MSc., FMCPH., PhD.
59
60

1
2
3 **1 REFERENCES**
4
5
6

- 7 2 1 Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver
8 3 disease—Meta-analytic assessment of prevalence, incidence, and outcomes, *Hepatology*
9 4 2016;64:73-84.
- 10
11 5 2 Kwon Y, Oh S, Hwang S, et al. Association of nonalcoholic fatty liver disease with components of
12 6 metabolic syndrome according to body mass index in Korean adults, *Am J Gastroenterol*
13 7 2012;107:1852.
- 14
15
16 8 3 Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus—
17 9 present and future perspectives, *Nature Reviews Endocrinology* 2012;8:228-36.
- 18
19
20 10 4 Perseghin G. The role of non-alcoholic fatty liver disease in cardiovascular disease, *Dig Dis*
21 11 2010;28:210-3.
- 22
23
24 12 5 Musso G, Gambino R, Cassader M, et al. Meta-analysis: natural history of non-alcoholic fatty liver
25 13 disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity, *Ann Med*
26 14 2011;43:617-49.
- 27
28
29 15 6 Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty
30 16 liver disease: Practice Guideline by the American Association for the Study of Liver Diseases,
31 17 American College of Gastroenterology, and the American Gastroenterological Association,
32 18 *Hepatology* 2012;55:2005-23.
- 33
34
35 19 7 Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of
36 20 hepatic steatosis in the general population, *BMC Gastroenterol* 2006;6:33.
- 37
38
39 21 8 Fedchuk L, Nascimbeni F, Pais R, et al. Performance and limitations of steatosis biomarkers in
40 22 patients with nonalcoholic fatty liver disease, *Aliment Pharmacol Ther* 2014;40:1209-22.
- 41
42
43 23 9 Jung C, Lee W, Hwang J, et al. Assessment of the fatty liver index as an indicator of hepatic
44 24 steatosis for predicting incident diabetes independently of insulin resistance in a Korean
45 25 population, *Diabetic Med* 2013;30:428-35.
- 46
47
48 26 10 Onat A, Can G, Kaya A, et al. Fatty liver disease: Disparate predictive ability for cardiometabolic
49 27 risk and all-cause mortality, *World J Gastroenterol* 2015;21:13555-65.
- 50
51
52 28 11 Salonen JT. Is there a continuing need for longitudinal epidemiologic research? The Kuopio
53 29 Ischaemic Heart Disease Risk Factor Study, *Ann Clin Res* 1988;20:46-50.
- 54
55
56 30 12 Salonen JT, Seppanen K, Nyyssonen K, et al. Intake of mercury from fish, lipid peroxidation, and
57 31 the risk of myocardial infarction and coronary, cardiovascular, and any death in eastern Finnish
58 32 men, *Circulation* 1995;91:645-55.
- 59
60 33 13 Räsänen J, Kauhanen J, Lakka T, et al. Religious affiliation and all-cause mortality: a prospective
61 34 population study in middle-aged men in eastern Finland, *Int J Epidemiol* 1996;25:1244-9.

- 1
2
3 1 14 Laukkanen JA, Pukkala E, Rauramaa R, et al. Cardiorespiratory fitness, lifestyle factors and
4 2 cancer risk and mortality in Finnish men, *Eur J Cancer* 2010;46:355-63.
5
6
7 3 15 Willenbring ML, Massey SH, Gardner MB. Helping Patients Who Drink Too Much: An Evidence-
8 4 Based Guide for Primary Care Physicians. *Am Fam Physician* 2009;80.
9
10 5 16 McGuire S. U.S. Department of Agriculture and U.S. Department of Health and Human Services,
11 6 Dietary Guidelines for Americans, 2010. 7th Edition, Washington, DC: U.S. Government Printing
12 7 Office, January 2011, *Adv Nutr* 2011;2:293-4.
13
14
15 8 17 Fawehinmi TO, Ilomäki J, Voutilainen S, et al. Alcohol consumption and dietary patterns: the
16 9 FinDrink study, *PLoS One* 2012;7:e38607.
17
18
19 10 18 Virtanen JK, Mursu J, Tuomainen TP, et al. Dietary fatty acids and risk of coronary heart disease
20 11 in men: the Kuopio Ischemic Heart Disease Risk Factor Study, *Arterioscler Thromb Vasc Biol*
21 12 2014;34:2679-87.
22
23
24 13 19 Kauhanen J, Kaplan GA, Goldberg DE, et al. Pattern of alcohol drinking and progression of
25 14 atherosclerosis, *Arterioscler Thromb Vasc Biol* 1999;19:3001-6.
26
27 15 20 Alberti K. International Diabetes Federation Task Force on Epidemiology and Prevention;
28 16 National Heart, Lung, and Blood Institute; American Heart Association; Wo, *Circulation*
29 17 2009;120:1640-5.
30
31
32 18 21 Cheema JR. Some general guidelines for choosing missing data handling methods in educational
33 19 research, *Journal of Modern Applied Statistical Methods* 2014;13:3.
34
35
36 20 22 Jäger S, Jacobs S, Kröger J, et al. Association between the fatty liver index and risk of type 2
37 21 diabetes in the EPIC-Potsdam Study, *PLoS one* 2015;10:e0124749.
38
39 22 23 Nishi T, Babazono A, Maeda T, et al. Evaluation of the fatty liver index as a predictor for the
40 23 development of diabetes among insurance beneficiaries with prediabetes, *Journal of diabetes*
41 24 *investigation* 2015;6:309-16.
42
43
44 25 24 Balkau B, Lange C, Vol S, et al. Nine-year incident diabetes is predicted by fatty liver indices: the
45 26 French D.E.S.I.R. study, *BMC Gastroenterol* 2010;10:56,230X-10-56.
46
47
48 27 25 Shibata M, Kihara Y, Taguchi M, et al. Nonalcoholic fatty liver disease is a risk factor for type 2
49 28 diabetes in middle-aged Japanese men, *Diabetes Care* 2007;30:2940-4.
50
51 29 26 Bedogni G, Bellentani S. Fatty liver: how frequent is it and why, *Ann Hepatol* 2004;3:63-5.
52
53
54 30 27 Karajamaki AJ, Bloigu R, Kauma H, et al. Non-alcoholic fatty liver disease with and without
55 31 metabolic syndrome: Different long-term outcomes, *Metabolism-Clinical and Experimental*
56 32 2017;66:55-63.
57
58
59 33 28 Valenti L, Bugianesi E, Pajvani U, et al. Nonalcoholic fatty liver disease: cause or consequence of
60 34 type 2 diabetes? *Liver International* 2016;36:1563-79.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 29 Targher G, Byrne CD. Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for
2 type 2 diabetes and its complications, *The Journal of Clinical Endocrinology & Metabolism*
3 2013;98:483-95.


4 30 Olubamwo OO, Virtanen JK, Voutilainen A, et al. Association of fatty liver index with the risk of
5 incident cardiovascular disease and acute myocardial infarction, *Eur J Gastroenterol Hepatol*
6 2018;30:1047-54.

7 31 Yang BL, Wu WC, Fang KC, et al. External validation of fatty liver index for identifying
8 ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan, *PLoS One*
9 2015;10:e0120443.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Variation of hazard ratio of incident type 2 diabetes with baseline fatty liver index



1
2
3 **APPENDIX**4
5 **Table 1 – Association of baseline fatty liver index with incident type 2 diabetes after excluding**
6
7 **smokers**

FLI	Number of subjects (% with T2D) (IR)	Model 1 HR (95% CI)	Model 2 HR (95% CI)
FLI*	1221(22.4) (11)	1.014(1.008-1.021)	1.016(1.009-1.022)
FLI category			
≤30 (Ref.)	549 (13.5) (7)	1.000	1.000
30-<60	380(23.9) (12)	1.43(1.02-1.99)	1.69(1.23-2.33)
≥60	292(37.0) (21)	2.24(1.54-3.26)	2.38(1.65-3.44)
P-trend	-	<0.001	<0.001

4 FLI – fatty liver index, FLI* - FLI uncategorized, HR – hazard ratio. CI – confidence interval. T2D – type 2 diabetes, IR –
5 Incidence rate per 1000 person-years

6 Model 1: FLI, age, examination date, family history of diabetes, alcohol consumption per week, physical activity, fruit-
7 berry-vegetable consumption, C-reactive protein, leukocytes albumin, fibrinogen, and ferritin, systolic blood pressure,
8 diastolic blood pressure, insulin, fasting glucose, LDL, and HDL.

9 Model 2: FLI, age, examination date, family history of diabetes, alcohol consumption per week, physical activity, fruit-
10 berry-vegetable consumption, C-reactive protein, leukocytes albumin, fibrinogen, and ferritin, metabolic syndrome
11 status.

12 ^a Other independent predictors of T2D in the model were family history of diabetes, serum ferritin, alcohol
13 consumption, and fasting glucose.

14 ^b Other independent predictors of T2D in the model were family history of diabetes, serum ferritin, alcohol
15 consumption, and metabolic syndrome status. HR metabolic syndrome = 1.76(1.28-2.41).

16

17

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cohort studies

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1, 2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	2, 5
Methods			
Study design	4	Present key elements of study design early in the paper	6-8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	7, 9-10
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	9-10
		(c) Explain how missing data were addressed	9
		(d) If applicable, explain how loss to follow-up was addressed	8
		(e) Describe any sensitivity analyses	9-10
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	7 - -
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	11, Table 1 7, 9 11
Outcome data	15*	Report numbers of outcome events or summary measures over time	11, Tables 2 & 3
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9-11, Tables 2 & 3 9-11, Tables 2 & 3 NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	12, Table 4 & 5, Figure 1
Discussion			
Key results	18	Summarise key results with reference to study objectives	20
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	23-24
Generalisability	21	Discuss the generalisability (external validity) of the study results	23-24
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	25

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Association of Fatty Liver Index with risk of Incident Type 2 Diabetes by Metabolic Syndrome**
2 **Status in an Eastern Finland Male Cohort**

3 Olubunmi O. Olubamwo¹, Jyrki K. Virtanen¹, Jussi Pihlajamäki^{1,2}, Tomi-Pekka Tuomainen¹

4
5 ¹ Institute of Public Health and Clinical Nutrition, Faculty of Health Sciences, University of Eastern
6 Finland, Kuopio, Finland.

7 ² Clinical Nutrition and Obesity Center, Kuopio University Hospital, KYS Kuopio, Finland.

8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

23 **Running head:** FLI and risk of T2D by MS status. Olubamwo et al.

24 **Word count:** main text 3864 words, abstract 267 words.

25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 *Corresponding author:

50 Olubunmi O, Olubamwo
51 Institute of Public Health and Clinical Nutrition
52 Faculty of Health Sciences
53 University of Eastern Finland, Kuopio,
54 P.O.Box 1627, FI-70211 Kuopio, Finland.
55 E-mail : olubunmi.olubamwo@uef.fi Tel : +358 403552905.

1 ABSTRACT

2 **Objective:** Fatty liver disease (FLD) is increasingly recognized as a predictor of cardiometabolic
3 risk. Our objective was to examine if metabolic syndrome (MS) status affects the association of
4 FLD with incident Type-2 diabetes (T2D) in middle-aged men.

5 **Design:** Prospective epidemiological study.

6 **Setting:** University affiliated research center in Kuopio, Eastern Finland.

7 **Participants:** our subjects were 1792 Finnish men without diabetes at baseline in the Kuopio
8 Ischaemic Heart Disease Risk Factor Study (KIHD) cohort.

9 **Outcome Measure:** Using fatty liver index (FLI), the association of baseline FLD with incident T2D
10 was analyzed in multivariable-adjusted Cox regression models, considering their MS statuses. The
11 main models were adjusted for constitutional factors, lifestyle factors, biomarkers of inflammation
12 and for high (FLI \geq 60) vs low (FLI $<$ 30) FLI categories.

13 **Results:** During a mean follow-up of 19 years, 375 incident cases of T2D were recorded. In the full
14 model, the hazard ratio (HR (95%CI)) for T2D was 3.68(2.80-4.82). The association was attenuated,
15 but maintained, with further adjustment for metabolic factors. When MS status was adjusted for in
16 place of metabolic factors, the HRs (95%CI) were 2.63(1.92-3.59) for FLI \geq 60 and 1.77(1.35-2.31) for
17 MS.

18 In MS-stratified analysis, FLI predicted T2D only among persons without MS. In unstratified analysis
19 with subjects categorized by FLI-MS, persons with FLI \geq 60 without MS had increased risk for T2D
20 (HR= 3.19(2.26-4.52)) compared with persons with FLI $<$ 30 without MS. Persons with FLI $<$ 30 and MS
21 had greater risk (HR= 4.31(2.15-8.61)) and, persons with both FLI \geq 60 and MS had the greatest risk
22 (HR=4.66(3.42-6.35)).

1
2
3 1 **Conclusion:** Generally, FLD (FLI \geq 60) predicts T2D. It specifically predicted T2D among men without
4
5 2 MS but not among men with MS, for whom MS alone already increases the risk. Both FLI and MS
6
7 3 can complement each other in screening and surveillance for persons at with increased T2D risk.
8
9

10 4
11
12
13 5 **KEY WORDS:** fatty liver index, fatty liver disease, type 2 diabetes, metabolic syndrome, predictor,
14
15 6 metabolic factors, Kuopio Ischaemic Heart Disease Risk Factor Study
16
17
18
19 7

20 21 22 8 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- 23 9 • The study is population-based and the design is prospective, with long follow-up.
- 24 10 • We adjusted for a range of constitutional factors, lifestyle factors and biomarkers keeping
25 11 in cognizance the components of both major exposure variables to avoid overadjustment.
- 26 12 • The study population comprised of men only.
- 27 13 • Fatty Liver Index used as a surrogate of fatty liver does not detect progression of fatty liver
28 14 disease.
- 29 15 • The statuses of the men with respect to viral hepatitis were not established at baseline,
30 16 although, viral hepatitis have remained low in the Finnish population.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 INTRODUCTION / BACKGROUND

2 There is increasing recognition of the fact that fatty liver disease (FLD), also known as hepatic
3 steatosis, is the commonest cause of chronic liver disease worldwide. and that Also known as
4 hepatic steatosis, it FLD is associated with increased risk of cardiovascular disease (CVD) and Type
5 2 diabetes (T2D). Although the The prevalence has been observed to steadily rise; although, this
6 varies in different populations, it is also on the rise. Recent estimates suggest a global prevalence of
7 25% among adults, with but the highest prevalence occurs in the Middle East and South America
8 and while the lowest prevalence is in Africa [1]. The prevalence is estimated to be 24% in Europe
9 and more than 30% in developed countries [1]. Approximately one third of FLD patients progress to
10 steatohepatitis with fibrosis, which can thereafter progress to cirrhosis, liver failure and
11 hepatocellular carcinoma [1]. In addition, FLD Fatty Liver Disease is intimately linked with metabolic
12 diseases, including T2D and, it can be considered a predictor of metabolic diseases, even in the non-
13 obese population [2].

14 With this increasing recognition that While FLD is an acknowledged public health problem, there is
15 growing interest in FLD as a predictor of incident T2D as well [3]. A number of epidemiological
16 reports studies suggest that non-alcoholic fatty liver disease (NAFLD), diagnosed using either liver
17 enzymes or ultrasound scan (USS), is associated with an increase in T2D incidence [4, 5].

18 Liver biopsy, which is the gold standard for characterizing liver histology in patients with fatty liver.
19 The procedure is expensive and carries some morbidity and very rare mortality risks [6]. The fatty
20 liver index (FLI), an algorithm comprising of body mass index, waist circumference, gamma-glutamyl
21 transferase (GGT) and triglyceride concentrations. , It was developed by Bedogni et al., to predict
22 the presence of FLD. The algorithm has been widely validated, and is has gained increased
23 acceptance [7, 8]. There has have been reports of an association of high FLI (FLD) with incident T2D

1
2
3 1 [9], [10]. However, with FLD being intimately linked with metabolic diseases, it is not known
4
5
6 2 uncertain whether if the predictive ability of FLD is independent of presence of established
7
8 3 metabolic syndrome (MS), a known potent predictor of T2D.

9
10 4 Therefore, using FLI as a surrogate for FLD, we examined whether MS status affects the association
11
12
13 5 of FLD, with incident T2D in middle-aged men.
14

15 6

16
17
18 7

19
20
21 8

22
23
24 9

25
26
27 10

28
29
30 11

31
32
33 12

34
35
36 13

37
38
39 14

40
41
42 15

43
44
45 16

46
47
48 17

49
50
51 18

52
53
54 19

55
56
57 20

58
59
60

For peer review only

1 METHODS

2 **Study population:** Our study population consisted of comprised participants in the Kuopio
3 Ischaemic Heart Disease Risk Factor Study (KIHD). The KIHD study is a prospective population-based
4 study. It was designed to investigate risk factors for CVDs and related outcomes, in middle-aged and
5 ageing men, from Eastern Finland. The original study population consisted of an age-stratified
6 sample of 2682 men. They These were enrolled in at baseline examinations between March 1984
7 and December 1989. The men were 42, 48, 54, or 60 years of age at baseline. The study was
8 approved by the Research Ethics Committee of the University of Kuopio [11], and the subjects gave
9 their written consent.

10 **Data Collection:** Data were collected through using self-administered questionnaires, interviews,
11 physical examinations, and various blood tests which aimed to elucidate determine physiological
12 and biochemical parameters [12, 13]. The self-administered questionnaires were was used to collect
13 data on medical history, including history of type 2 diabetes, metabolic diseases, liver disease, etc.,
14 medication history, family history of diabetes, and family history of CVD[12]. Data on lifestyle,
15 including physical activity, history of smoking habit, history of alcohol consumption, and diet, were
16 also collected [14]. Categorisation of alcohol consumption was done according to standard
17 guidelines by the National Institute of Alcohol Abuse and Alcoholism [15] and Dietary Guidelines for
18 Americans 2010 [16] as already published [17].

19 **The** A family history of CVD or diabetes was defined as positive if the father, mother, sister, or
20 brother of the subject had a history of CVD or diabetes. [12]. A subject was defined as a smoker if
21 he had ever smoked on a regular basis and had smoked cigarettes, cigars, or pipe within the previous
22 30 days. Dietary intakes including fruit, berry and vegetable consumption were assessed with a 4-
23 day food recording [18].

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Physical examinations included anthropometric measurements and indices, vital signs, and physiologic measurements. All physical measurements were measured made following standard protocols. Waist circumference was calculated as the mean of waist circumferences taken at maximal inspiration and that taken at maximal expiration. Body mass index (BMI) was computed as the ratio of weight in Kg to the square of height in meters (kg/m²). Blood pressure, which was measured by two separate nurses, was taken as the mean of three measurements taken in the supine, one on standing and two in sitting position with 5-minute intervals [19].

Specimen collection and laboratory measurements- Blood samples were collected between 08.00 and 10.00 hours after 3 days of abstinence from alcohol ingestion and a 12-hour abstinence from smoking and eating. Data on complete blood count, serum electrolytes, Homeostatic model assessment of insulin resistance (HOMA1-IR), fasting glucose, lipoprotein fractions (including total cholesterol, HDL cholesterol, LDL cholesterol, serum triglycerides), liver function tests including albumin, gamma-glutamyl transferase, fibrinogen, ferritin, and biomarkers like C-reactive protein (CRP), were each determined from appropriately collected and processed samples. Detailed description of the KIHD has been published elsewhere [11].

Included and excluded subjects: The initial number of men at baseline was 2682. Of these, we excluded 40 men with history of physician diagnosed liver or pancreas disease, and 162 men with history of diabetes. Of the remaining 2480 men, 1792 who had complete data for FLI calculation, were included in the analyses.

Measuring the components of the Fatty liver index: We calculated FLI using the algorithm developed by Bedogni et al [7]. The algorithm, incorporates four variables: BMI, waist circumference, serum triglycerides, and serum gamma-glutamyl transferase (GGT), and is expressed as follows:

$$FLI = \frac{(e^{0.953 \times \ln(\text{triglycerides}) + 0.139 \times \text{BMI} + 0.718 \times \ln(\text{ggT}) + 0.053 \times \text{waist circumference} - 15.745})}{(1 + e^{0.953 \times \ln(\text{triglycerides}) + 0.139 \times \text{BMI} + 0.718 \times \ln(\text{ggT}) + 0.053 \times \text{waist circumference} - 15.745})} \times 100$$

Where triglycerides is in mg/dl, waist circumference in cm, and BMI in Kg/m². We categorized FLI in accordance with Bedogni **et al**'s categorization, as low FLI (<30), intermediate FLI (30-<60), and moderate-high FLI (>60), indicating no fatty liver, indeterminate, and fatty liver, respectively.

Defining Metabolic Syndrome Status: MS was defined in accordance with the harmonized criteria for diagnosis of MS [20]. The presence of any **3** **three** of the following **5** **five** risk factors constitutes a diagnosis of metabolic syndrome: waist circumference ≥120 cm; serum triglycerides ≥150 mg/dL (1.7 mmol/L) (or drug treatment for elevated triglycerides); HDL cholesterol <40 mg/dL (1.0 mmol/L) (or drug treatment for reduced HDL cholesterol); blood pressure with systolic ≥130 and/or diastolic ≥85 mm Hg (or antihypertensive drug treatment in a patient with a history of hypertension); fasting glucose ≥100 mg/dl (or drug treatment of elevated glucose), [20].

Outcome Definitions: We defined incident T2D outcomes as self-reported physician-set diagnosis of T2D and/or; fasting plasma glucose ≥7.0mmol/L or 2-h oral glucose tolerance test plasma glucose ≥11.1 mmol/L at re-examination rounds 4, 11, and 20 years after the baseline and; T2D information derived by record linkage to either the national hospital discharge registers or to the Social Insurance Institution of Finland register for reimbursement of medicine expenses used for T2D. **Detection of T2D by self-report of physician diagnosed T2D was followed by either detection via the hospital discharge registers or National drug reimbursement register. The proportion of the data obtained by the record linkage are as follows: hospital discharge registers 42%, and National drug reimbursement register 58%. T2D cases that were included were those coded in the Tenth International Classification of Diseases (ICD 10 code numbers from E11.0 to E11.9).**

1
2
3 1 **Patient and public involvement:** The study was carried out at in a non-patient research facility. All
4
5
6 2 the study participants were volunteers. Neither the study participants nor the public were involved
7
8 3 in the design of the study.
9

10
11 4
12
13 5 **Statistical Methods:** All statistical analyses were performed using SPSS software Version 21.0 for
14
15
16 6 Windows (IBM, Chicago, IL). In all analyses, two-sided alpha <0.05 was considered statistically
17
18 7 significant.
19

20
21 8 Descriptive analyses were performed to summarise baseline characteristics of participants
22
23 9 according to baseline FLI categories. For continuous variables, we used Jonckheere trend test to test
24
25
26 10 for linear trend across FLI categories. For categorical variables, we used Chi-Square test to test for
27
28 11 linear association across FLI categories. To make up for missing 0.4% values (spread across 50% of
29
30
31 12 the variables and 13.4% of subjects), we used a regression based multiple imputation method (40
32
33 13 iterations) according to guideline by Cheema 2014 [21].
34

35
36 14 After confirmation of proportionality of hazards, we proceeded with implemented a multivariable-
37
38 15 adjusted Cox proportional hazards model analysis, to analyze examine the association relationship
39
40
41 16 of between baseline FLI with and incident T2D in considering metabolic factors and the MS statuses
42
43
44 17 of the subjects as follows:
45

46
47 18 First, we analyzed the overall association overall, adjusting for MS status. The models were as
48
49 19 follows: model 1- Examination year, constitutional factors (age and family history of T2D), lifestyle
50
51 20 factors (smoking pack years, alcohol consumption, physical activity and, consumption of fruits,
52
53
54 21 berries and vegetables) and, inflammatory markers (C-reactive protein, leukocyte count,
55
56 22 thrombocyte count), and metabolic factors (fasting glucose, insulin, HDL, LDL, systolic blood
57
58
59 23 pressure, diastolic blood pressure); model 2- Examination year, constitutional factors (age and
60

1
2
3 1 family history of T2D), lifestyle factors (smoking pack years, alcohol consumption, physical activity
4
5
6 2 and, consumption of fruits, berries and vegetables) and, inflammatory markers (C-reactive protein,
7
8 3 leukocyte count, thrombocyte count), and MS status.

9
10
11 4 In sensitivity analyses of overall analysis association, we excluded men with a high weekly alcohol
12
13
14 5 consumption of ≥ 168 g [17] before analyzing the overall association of FLI with T2D in multivariable
15
16 6 adjusted Cox proportional hazards as explained above. In addition, we excluded smokers before
17
18 7 analyzing the overall association of FLI with T2D in multivariable adjusted Cox proportional hazards.

19
20
21 8 Secondly, we performed sub-group analyses in which we stratified our study sample by MS status.
22
23
24 9 in stratified analyses, we stratified our population sample by MS status. We then performed
25
26 10 multivariable-adjusted Cox proportional hazards analysis with adjustment for covariates to observe
27
28
29 11 if the association of FLI with incident T2D differs by MS status in model 1 and 2 as explained above,
30
31 12 but excluding fasting glucose in model 2.

32
33
34 13 Thirdly, for clearer understanding of the relation of the associations considering both FL and MS
35
36 14 statuses, using the combination of FLI category and MS status as a composite variable, we
37
38 15 performed multivariable-adjusted Cox proportional hazards analysis on the study population with
39
40 16 adjustment for covariates as in model 1 above, to elaborate the variation of the association by MS
41
42 17 status.

1 RESULTS

2
3
4
5
6 2 **Characteristics of the study population:** The baseline characteristics of the study population (1792
7
8
9 3 men) according to FLI categories are shown in Table 1. In general, the mean values and proportions
10
11 4 for men in the intermediate FLI category were in between estimates for the lowest (reference) FLI
12
13 5 category and estimates for the highest FLI category. Compared with the low FLI category, men in
14
15
16 6 the high FLI category had a greater proportion of men with family history of diabetes, and a greater
17
18 7 proportion with family history of CVD. Men in the high FLI category They consumed less fruit, berries
19
20
21 8 and vegetables, and had a higher proportion of more likely to be heavy alcohol consumers. but a
22
23 9 lower proportion of smokers. They had higher mean waist circumference and mean BMI and they
24
25
26 10 were more likely to be hypertensive. They also had higher GGT levels, higher triglyceride, higher
27
28 11 fasting insulin, higher blood glucose, lower HDL cholesterol and higher levels of markers of systemic
29
30
31 12 inflammation. Generally, the range of values of the fasting blood glucose for the eligible men was
32
33 13 between 3.1 mmol/l (minimum) and 6,2 mmol/l (or 112mg/dl) (maximum).

34
35
36 14 **Multivariable proportional hazards model analyses:** During a mean (SD) follow-up of 18.8(6.6)
37
38
39 15 years, there were 375 cases of incident T2D. The incidence rates for T2D were 11 cases per 1000
40
41 16 person-years. Significantly lower survival free of incident T2D was noted for participants in high
42
43
44 17 baseline FLI category compared to the low (normal) FLI category at baseline (Log-rank < 0.001).
45
46 18 Subjects in intermediate FLI category also separated clearly from those with Low FLI for incident
47
48
49 19 T2D.

20 **Relation between baseline Fatty Liver Index and incident T2D**

51
52
53
54 21 **Overall analyses:** Table 2 shows the association of FLI with incident T2D. In model 1, the HRs for
55
56
57 22 incident T2D was 42% higher for the intermediate category, and 113% higher for the high FLI
58
59 23 category, when compared with the low category. The association was maintained, though
60

1 attenuated in model 2, and in model 2 with MS where high FLI category was associated with 163%
2 increased risk. MS was also independently associated with incident T2D in the model, with 77%
3 increased risk (HR (95%CI) 1.77(1.35-2.31)).

4 *Sensitivity analyses* - after exclusion of 241 men who were heavy alcohol consumers (Table 3), the
5 results were similar to those obtained in the analyses with the whole sample, as shown in Table 2.

6 Similarly, after exclusion of 571 men who were smokers (Appendix), the results were similar to those
7 obtained in the analyses with the whole sample, as shown in Table 1 of the appendix.

8 Further exploration of the association of FLI with incident T2D across FLI categories of 10 (see Figure
9 1) reveals steady increase in HR across the categories without any threshold areas. When we
10 analyzed our data with FLI as continuous variable, a unit increase in FLI was associated with 1.7%
11 increase in HR (in the analyses with the whole sample), and 1.8% increase (after exclusion heavy
12 alcohol consumers), as shown in Tables 2 and 3.

13 **Stratified analyses:** Table 4 shows the results of Cox regression analysis when we stratified by MS
14 status. Among those In the stratus without MS, high FLI was associated with over 100% increased
15 risk of T2D when compared with those in the low FLI category, high FLI was associated with over
16 100% increased risk of T2D. Among those with MS, high FLI was not associated with additional risk
17 when compared with those in the low FLI category high FLI was not associated with additional risk.

18 **Analysis with composite FLI-MS variable:** In additional sensitivity analyses, with the combination of
19 FLI category and MS status as composite exposure variable, when compared with subjects having
20 neither fatty liver nor MS, having high FLI with no MS was associated with 219% increase in risk (the
21 HR (95%CI) was 3.19(2.26-4.51)). Having normal FLI with MS was associated with 331% increased
22 risk (the HR (95%CI) was 4.31(2.15-8.61)) and, persons having high FLI and MS were at greatest risk,
23 with 366% increase in risk (HR (95%CI) 4.66(3.42-6.35)). The presence of MS was associated with
24 greater risk in intermediate and high FLI categories (the HRs (95%CI) were 3.77(2.50-5.70) for

1 presence of MS with intermediate FLI category, and 4.66(3.42-6.35) for the presence of MS with
 2 high FLI category).

3 **Table 1 - Baseline characteristics of 1792 men according to fatty liver index (FLI) categories**

Characteristic	FLI<30	FLI=30-< 60	FLI≥60	P-trend*
	Mean (SD)	Mean (SD)	Mean (SD)	
	or n (%)	or n (%)	or n (%)	
	N=833	N=552	N=407	
FLI	16.2 (7.7)	43.3 (8.1)	76.8 (10.6)	<0.001
Constitutional factors				
Age in years	52.6 (5.6)	53.4 (5.5)	52.5 (5.6)	0.251
Family history of diabetes	212 (25.5%)	145 (27.8%)	108 (26.5%)	0.651
Family history of CVD	667 (80.1%)	459 (83.2%)	341 (83.8%)	0.072
Lifestyle factors				
Smoking pack years	7.5(16.0)	8.4(16.8)	6.8(13.6)	0.785
Alcohol consumption (g/week)	55 (89)	78 (117)	116 (165)	<0.001
Physical activity (Energy exp.) (kcal/day)	136(156)	147(175)	129(192)	0.36
Fruit, berry and vegetable consumption (g/day)	265 (171)	261 (148)	233 (147)	0.023

**Anthropometrics and
physiologic
measurements**

Mean waist circumference (cm)	83.9 (6.1)	92.7 (5.2)	101.8 (8.1)	<0.001
BMI (kg/m ²)	24.4 (2.0)	27.3 (1.9)	30.7 (3.1)	<0.001
Mean systolic bp	135.5(17.0)	135.7(17.8)	135.9(18.1)	<0.001
Mean diastolic bp	89.4(10.5)	88.5(10.6)	89.6(11.1)	<0.001
Hypertension	259 (31.1%)	275 (49.8%)	261 (64.1%)	<0.001

Biomarkers

Insulin	8.3 (3.0)	11.2 (4.4)	16.6 (9.7)	<0.001
Glucose (mmol/L)	4.5 (0.4)	4.6 (0.5)	4.8 (0.5)	<0.001
HOMA1-IR insulin resistance	1.86 (0.71)	2.60 (1.10)	3.91 (2.30)	<0.001
Total cholesterol (mmol/L)	5.71 (1.07)	5.93 (1.02)	6.05 (1.00)	<0.001
HDL cholesterol (mmol/L)	1.38 (0.32)	1.25 (0.26)	1.20 (0.27)	<0.001
LDL cholesterol (mmol/L)	3.91 (1.01)	4.09 (0.97)	4.01 (0.93)	0.04
Triglycerides (mmol/L)	0.94 (0.40)	1.35 (0.62)	1.93 (1.02)	<0.001
Gamma-glutamyl transferase (U/L)	18 (11)	28 (20)	51 (47)	<0.001

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Albumin	42 (4)	42 (4)	43 (3)	<0.001
C- reactive protein (m/L)	1.86 (4.46)	2.61 (4.54)	3.15 (4.26)	<0.001
Ferritin (µg/L)	128 (100)	172 (157)	235 (186)	<0.001
Fibrinogen g/L	2.92 (0.58)	3.06 (0.57)	3.10 (0.55)	<0.001
Leukocyte count x10 ⁹ /L	5.4 (1.6)	5.7 (1.6)	5.9 (1.6)	<0.001
Metabolic syndrome and medication use history				
Metabolic syndrome	29 (3.5%)	91 (16.5%)	238 (58.5%)	<0.001
Drug for high cholesterol	7 (0.84%)	2 (0.36%)	6 (1.47%)	0.509
Drug for hypertension	111 (13.32%)	127 (23.05%)	141(34.56%)	<0.001

*Jonckheere trend test for continuous variable. Chi-Square linear-by-linear association for categorical variables. bp- blood pressure

1 DIABETES PREDICTION

2 **Table 2 – General association of baseline fatty liver index (FLI) with incident type 2 diabetes**

FLI	Number of subjects (%) with T2D (IR)	Model 1 HR (95% CI)	Model 1 HR (95% CI)	Model 2 HR (95% CI)
FLI*	1792 (20.9) (11)	1.022(1.018-1.027)	1.013(1.007-1.018) ^a	1.017(1.012-1.022) ^b
FLI category				
≤30 (Ref.)	833 (12.1) (6)	1.000	1.000	1.000
30-<60	552 (22.6) (12)	1.98(1.52-2.59)	1.42(1.07-1.88)	1.81(1.38-2.37)
≥60	407 (36.6) (22)	3.68(2.80-4.82)	2.13(1.56-2.93) ^a	2.63(1.92-3.59) ^b
P-trend	-	<0.001	<0.001	<0.001

3 *FLI uncategorized, HR – hazard ratio. CI – confidence interval. T2D – type 2 diabetes, IR – Incidence rate per 1000 person-years

4 Model 1: FLI, age, examination date, family history of diabetes, smoking pack years, alcohol consumption per week, physical activity, fruit-berry-vegetable consumption, C-reactive protein, leukocytes albumin, fibrinogen, and ferritin.

5 Model 1: FLI, age, examination date, family history of diabetes, smoking pack years, alcohol consumption per week, physical activity, fruit-berry-vegetable consumption, C-reactive protein, leukocytes albumin, fibrinogen, and ferritin, systolic blood pressure, diastolic blood pressure, insulin, fasting glucose, LDL, and HDL.

6 Model 2: FLI, age, examination date, family history of diabetes, smoking pack years, alcohol consumption per week, physical activity, fruit-berry-vegetable consumption, C-reactive protein, leukocytes albumin, fibrinogen, and ferritin, and metabolic syndrome status.

7 ^a Other independent predictors of T2D in the model were family history of diabetes, serum ferritin, hypertension, serum insulin, and glucose.

^b Other independent predictors of T2D in the model were family history of diabetes, serum ferritin and metabolic syndrome status. HR metabolic syndrome = 1.77(1.35-2.31).

Table 3 – Association of baseline fatty liver index with incident type 2 diabetes after excluding men with high alcohol intake

FLI	Number of subjects (% with T2D) (IR)	Model 1 HR (95% CI)	Model 1 HR (95% CI)	Model 2 HR (95% CI)
FLI*	1548(20.9) (11)	1.023(1.018-1.027)	1.014(1.008-1.019)	1.018(1.012-1.024)
FLI category				
≤30 (Ref.)	771(12.5) (6)	1.000	1.000	1.000
30-<60	472(23.1) (12)	1.96(1.48-2.60)	1.43(1.06-1.93)	1.78(1.33-2.37)
≥60	305(38.7) (23)	3.61(2.71-4.81)	2.21(1.57-3.10)	2.63(1.89-3.66)
P-trend	-	<0.001	<0.001	<0.001

FLI – fatty liver index, FLI* - FLI uncategorized, HR – hazard ratio. CI – confidence interval. T2D – type 2 diabetes, IR – Incidence rate per 1000 person-years

Model 1: FLI, age, examination date, family history of diabetes, smoking pack years, alcohol consumption per week, physical activity, fruit-berry-vegetable consumption, C-reactive protein, leukocytes albumin, fibrinogen, and ferritin.

Model 1: FLI, age, examination date, family history of diabetes, smoking pack years, alcohol consumption per week, physical activity, fruit-berry-vegetable consumption, C-reactive protein, leukocytes albumin, fibrinogen, and ferritin, systolic blood pressure, diastolic blood pressure, insulin, fasting glucose, LDL, and HDL.

Model 2: FLI, age, examination date, family history of diabetes, smoking pack years, alcohol consumption per week, physical activity, fruit-berry-vegetable consumption, C-reactive protein, leukocytes albumin, fibrinogen, and ferritin, and metabolic syndrome status.^a Other independent predictors of T2D in the model were family history of diabetes, serum ferritin, hypertension, serum insulin, and fasting glucose.

^b Other independent predictors of T2D in the model were family history of diabetes, serum ferritin and metabolic syndrome status. HR metabolic syndrome = 1.65(1.24-2.21).

1
2
3 **Table 4 – Association of fatty liver index (FLI) with incident type 2 diabetes by metabolic**
4 **syndrome status (sub-analyses)**
5

No metabolic syndrome	Number of subjects (% with T2D) (IR)	Model 1 HR(95%CI)	Model 2 HR(95%CI)
FLI*	1427(16.7) (9)	1.021 (1.015-1.027)	1.017 (1.010-1.025) ^a
FLI category			
≤30 (Ref.)	803(11.5) (6)	1.00	1.00 ^b
30-<60	456(20.0) (11)	1.81(1.33-2.46)	1.58(1.14-2.19)
≥60	168(33.3) (18)	3.07(2.14-4.41)	2.38(1.58-3.58)
p-trend		<0.001	<0.001
Metabolic syndrome	Number of subjects (% with T2D) (IR)	Model 1 HR(95%CI)	Model 2 HR(95%CI)
FLI*	358(37.7)(24)	1.007(0.997-1.016)	0.996(0.992-1.000) ^c
FLI category			
≤30 (Ref.)	29(31.0) (23)	1.000	1.000 ^d
30-<60	91(36.3) (21)	0.77(0.35-1.70)	0.80(0.59-1.09)
≥60	238(39.1) (25)	1.02(0.49-2.16)	0.79 (0.58-1.06)
p-trend		0.42	0.22
Category by FLI and MS status	Number of subjects (% with T2D) (IR)	Model 1 HR(95%CI)	
FLI≤30 MS ⁻	803(11.5) (6)	1.000	-
FLI30-<60MS ⁻	456(20.0) (11)	1.79(1.33-2.41)	-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FLI \geq 60MS ⁻	168(33.3) (18)	3.19(2.26-4.51)	-
FLI \leq 30 MS ⁺	29(31.0) (23)	4.31(2.15-8.61)	-
FLI30-<60MS ⁺	91(36.3) (21)	3.77(2.50-5.70)	-
FLI \geq 60MS ⁺	238(39.1) (25)	4.66(3.42-6.35)	-

*FLI uncategorized, Ref – reference. HR – hazard ratio. CI – confidence interval. T2D – type 2 diabetes, IR – Incidence rate per 1000 person-years

*Statistically significant at $P \leq 0.05$. MS – Metabolic syndrome. MS⁻ - Metabolic syndrome negative. MS⁺ - Metabolic syndrome positive.

Model 1: FLI, age, examination date, family history of diabetes, smoking pack years, alcohol consumption per week, physical activity, fruit-berry-vegetable consumption, C-reactive protein, leukocytes, thrombocytes, fibrinogen, and ferritin.

Model 2: Model 1 plus systolic blood pressure, diastolic blood pressure, insulin, **fasting glucose**, LDL, and HDL

^a Other independent predictors of T2D in the model were serum ferritin and insulin.

^b Other independent predictors of T2D in the model were serum ferritin and insulin.

^c Independent predictors of T2D in the model were fasting glucose and insulin.

^d Independent predictors of T2D in the model were fasting glucose and insulin.

Figure 1 – Graph of FLI and risk of incident T2D.

DISCUSSION

We examined the association of FLI, as a surrogate of fatty liver disease, with in relation to incident T2D in a population of middle-aged men, considering while taking the baseline MS status into account. Specifically, we We found that although FLD assessed by FLI predicts the risk of T2D in the whole study population, the association was strongest among those persons without MS at baseline.

Few studies have investigated the association of baseline FLI as categorized by Bedogni et al., with incident T2D [10, 22]. Jager et al.[22] and Onat et al. [10], studied the association of FLI with incident T2D in healthy populations, followed up for eight years. Nishi et al.[23], studied the association of FLI with incident T2D in a population of prediabetic subjects followed up for three years[23].

A few studies, Balkau et al.[24] and Jung et al.[9] also reported the association of FLI with incident T2D using FLI categorization different from that proposed by Bedogni et al. [9, 24]. Because previous studies on the association of FLI with incident T2D have adjusted for different groups of variables in their multivariable analyses models, we are careful in our comparison of findings.

Our finding that high FLI (FLI \geq 60) indicating fatty liver, as compared with low FLI(FLI<30) is associated with increased risk independent of constitutional and lifestyle factors, agrees with findings from previous studies findings by Jager et al.[22] and Onat et al.[10]. We found a 2 to 3-fold increased risk in our multivariable adjusted models. However, Jager et al., reported 11-fold increase while Onat et al reported a 5-fold increase. Our finding, that FLI 30-<60 intermediate FLI is also associated with increased risk of T2D, is also in line with reports by Jager et al.

Our finding that high FLI is associated with incident T2D even after adjusting for metabolic factors, agrees with other reports from Onat et al.[10], Balkau et al.[24] and Jung et al. [9], each of which used different cut-off points in categorizing FLI. Balkau et al. used FLI <20 and FLI \geq 70 as lower and upper cut-off points, and adjusted for glucose, insulin, and hypertension. Jung et al, used FLI<20 and

1
2
3 1 FLI ≥ 60 as lower and upper cut-off points. When we re-analyzed our data using these cut-off points,
4
5
6 2 the results (data not shown) did not differ markedly from what we present here.

7
8
9 3 Indeed, ultrasound diagnosed NAFLD has been shown to be associated with incident T2D and, the
10
11 4 association is not affected by adjustment for metabolic syndrome [5]. However, the predictability
12
13 5 of T2D independent of MS using FLI needs to be clarified.

14
15
16 6 We are unable to compare our findings on association of FLI with incident T2D in view of MS status
17
18 7 of the subjects, with previous studies on the association between FLI and incident T2D because
19
20
21 8 previous studies on the association did not consider the MS status of the subjects. However, our
22
23 9 finding, in our main analysis, that high FLI category is associated with increased risk of incident T2D
24
25
26 10 after adjusting for MS status agrees with this finding corroborates the report by Shibata et al.
27
28 11 [25]. Shibata et al. found that the presence of fatty liver, as diagnosed by ultrasonography, is
29
30
31 12 associated with increased risk of T2D when compared with those without fatty liver after adjusting
32
33 13 for age, BMI, smoking status, physical activity, and MS status [25].

34
35
36 14 The finding of similar results, after excluding men who were heavy consumers of alcohol, indicates
37
38 15 that our findings are also applicable to NAFLD. However, despite the multifactorial nature of the
39
40 16 aetiology of FLD, the relative contribution of heavy ethanol intake in the pathogenesis of fatty liver
41
42
43 17 is still uncertain [26]. Therefore, we did not exclude men with high alcohol intake in our main
44
45 18 analysis. The finding of similar results after excluding smokers proves further that smoking is not a
46
47
48 19 confounder in this target population.

49
50 20 It is remarkable that, when we stratified stratification by MS status did not reveal significant
51
52 21 association of high FLI with incident T2D in subjects with MS, the association of high FLI with incident
53
54
55 22 T2D did not reach statistical significance among subjects with MS, despite the fact that increasing
56
57 23 proportions of subjects with MS developed T2D across the FLI categories. This suggests that among
58
59
60 24 persons with MS, which is already a cluster of risk factors for T2D (including hyperglycaemia), high

1
2
3 1 FLI is likely not associated with significantly higher risk than that due to positive MS status alone. It
4
5
6 2 also suggests that the MS status was an effect modifier in the overall analysis.

7
8 3 Notwithstanding, our findings from the analysis with FLI-MS composite variable, are noteworthy. It
9
10 4 appears that FLI predicts risk of T2D in a dose-dependent manner among subjects without MS but
11
12
13 5 among subjects with MS, it does not predict risk of T2D in a dose-dependent manner. The additional
14
15 6 risk associated with high FLI appears less than that associated with MS positive status. Therefore,
16
17
18 7 the greatest risk was in subjects with both fatty liver and MS positivity. Our finding that the presence
19
20 8 of MS appears to be associated with higher risks than high FLI, may be consistent with the finding
21
22
23 9 by Käräjämäki et al [27]. However, Käräjämäki et al, observed from their data that, in the absence
24
25 10 of MS, fatty liver does not tend to pose a higher risk for development of T2D in comparison to
26
27
28 11 healthy subjects [27]. Our finding that, compared with healthy subjects (persons with normal FLI
29
30 12 and no MS), persons having high FLI and negative MS status were at increased risk, disagrees with
31
32
33 13 their observation.

34
35 14 Comparison of risks with FLI<10 as the reference reveals steady increase in risk across FLI (Figure 1).
36
37 15 This supports the suggestion that, even among subjects with intermediate FLI, the risk of incident
38
39
40 16 T2D increases with increasing FLI values.

41
42 17 Our findings can be explained in the light of current knowledge. It is thought that an initial
43
44
45 18 development of insulin resistance results in compensatory hyperinsulinemia and, together with
46
47 19 visceral obesity, promotes the development of FLD [28]. In return, the insulin resistant fatty liver
48
49 20 overproduces glucose and **VLDL** very low-density lipoprotein. This boosts mechanisms that lead to
50
51
52 21 exhaustion of pancreatic beta cell reserve, eventually leading to the development of T2D [28].
53
54 22 Steatotic and inflamed liver secretes hepatokines such as fetuin-A, fetuin-B, angiopoietin-like
55
56
57 23 proteins, fibroblast growth factor 21, and selenoprotein P, that have endocrine function at
58
59
60

1
2
3 1 extrahepatic sites to cause insulin resistance and other adverse effects on glucose homeostasis [29].

4
5 2 Hence, the association of high FLI with T2D.

6
7
8 3 Our finding that MS positive status is associated with higher risk than high FLI, and the co-occurrence

9
10 4 of MS with fatty liver is associated with the greatest risk, raises the suspicion that the MS

11
12 5 phenomenon represents a more advanced stage than FLD does, in the pathogenesis of T2D, as

13
14 6 proposed by Shibata et al [25], and suggested in recent epidemiological studies [27]. However, this

15
16 7 does not explain the population of persons with normal liver (low FLI) among people with MS.

17
18 8 The novel finding in our study is that although high FLI (FLD) is associated with increased risk incident

19
20 9 T2D, MS phenomenon, which may occur regardless of FLD, modifies this association. However, the

21
22 10 association is more clearly demonstrated when the reference group comprises of subjects with

23
24 11 normal liver and no MS. MS positive status can also predict T2D independent of FLI. In addition,

25
26 12 from our data, MS status is associated with higher risk than presence of fatty liver ($FLI \geq 60$). However,

27
28 13 FLI predicts T2D in subjects without MS. Although FLI appears to be a less efficient predictor of T2D

29
30 14 among subjects with MS, the co-presence of fatty liver and MS positive status is associated with

31
32 15 higher risk than that associated with MS alone. The reason why FLI did not predict T2D among MS

33
34 16 subjects is unclear. Our data revealed that among subjects with MS, the association conferred by

35
36 17 ggt and BMI (components variables of FLI that are not included in MS), is not significant when

37
38 18 compared with that conferred by insulin resistance and hyperglycaemia. However, this finding of

39
40 19 disparate association of FLD with T2D, by MS status, needs to be studied further.

41
42 20 Our current study findings have clinical implications. Firstly, we show that FLI, a surrogate of hepatic

43
44 21 steatosis, predicts risk of incident T2D especially in persons who are negative for MS. Secondly, the

45
46 22 association can be affected by metabolic factors or MS status. This suggests that FLD can also play

47
48 23 a role in the pathogenesis of T2D. Therefore, both FLD and MS are useful for screening risk of

49
50 24 incident T2D. From health systems perspective, because high FLI has also been associated with

1
2
3 1 increased risk of CVD [30], and it appears to be detectable before MS may be apparent, screening
4
5 2 with FLI may be more cost effective in asymptomatic persons. The finding of FLI in high category
6
7
8 3 should then prompt further evaluation for T2D and CVD.
9

10 4
11
12
13 5 Our study does have a number of limitations. Firstly, FLI as a surrogate of fatty liver does not detect
14
15 6 progression of FLD. Therefore, we are unable to differentiate the contribution of NASH and fibrosis
16
17 7 to the observed association. Another limitation of the study is that the hepatitis B and hepatitis C
18
19 8 statuses of the subjects were not established at baseline. The prevalence rate of hepatitis B and
20
21 9 hepatitis C, however, have remained low in the Finnish population (Karvonen 2016) (Safreed-
22
23 10 Harmon 2018). Also, our study population comprised of men only. There are reports that suggest
24
25 11 that lower FLI cut off values may apply to women [31]. We are unable to explore the influence of
26
27 12 gender on the predictability of T2D using FLI. Nevertheless, Bedogni et al., concluded that the
28
29 13 influence of gender in FLI is related to insulin and skinfold thickness, and probably insignificant [7].
30
31 14 The strength of our study lies in the prospective design. With this, we are able to demonstrate the
32
33 15 ability of FLI, a surrogate of hepatic steatosis, to predict incident occurrence of T2D. We have also
34
35 16 adjusted for a range of constitutional factors, lifestyle factors and biomarkers keeping in cognizance
36
37 17 the components of both major exposure variables, to control for the possible confounding factors
38
39 18 in the predictability of T2D using FLI.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 2 3 1 **CONCLUSION**

4
5
6 2 In conclusion, our data show that high FLI category (FLD), is associated with increased risk of incident
7
8 3 T2D, especially in men without MS. Persons with high FLI should be further evaluated for FLD and,
9
10 4 if found with FLD is present, they should be evaluated and monitored for T2D. FLD assessed using
11
12 5 FLI can be used as additional screening tool for persons at increased risk of incident T2D in the
13
14 6 general population. Both FLI and MS are useful, and can complement each other in screening and
15
16 7 surveillance of persons at increased risk of T2D. In such persons, appropriate preventive or
17
18 8 treatment measures should be instituted to improve their prognoses.
19
20
21
22
23
24
25

26 10 **Competing interests:**

27
28
29 11 The authors declare that they have no competing interests.
30
31

32 12 **Authors' contributions:**

33
34
35 13 OOO and T-PT conceived the study. OOO and T-PT designed the study. OOO performed the
36
37 14 statistical analyses. OOO wrote the first draft of the manuscript. JV , JP and T-PT contributed towards
38
39 15 development of this manuscript. All authors reviewed the final draft of the manuscript.
40
41
42

43 16 **Data sharing statement:**

44
45
46 17 No additional data are available.
47
48

49 18 **Acknowledgements:**

50
51
52 19 OOO received study grant from the Finnish Cultural Foundation Central, Finland (Suomen
53
54 20 Kulttuurirahasto), in partial support for the conduct of this study.
55
56

57
58 21 Language editing was by Enembe O Okokon MBBch., MSc., FMCPH., PhD.
59
60

1
2
3 **1 REFERENCES**
4
5
6

- 7 2 1 Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver
8 3 disease—Meta-analytic assessment of prevalence, incidence, and outcomes, *Hepatology*
9 4 2016;64:73-84.
- 10
11 5 2 Kwon Y, Oh S, Hwang S, et al. Association of nonalcoholic fatty liver disease with components of
12 6 metabolic syndrome according to body mass index in Korean adults, *Am J Gastroenterol*
13 7 2012;107:1852.
- 14
15
16 8 3 Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus—
17 9 present and future perspectives, *Nature Reviews Endocrinology* 2012;8:228-36.
- 18
19
20 10 4 Perseghin G. The role of non-alcoholic fatty liver disease in cardiovascular disease, *Dig Dis*
21 11 2010;28:210-3.
- 22
23
24 12 5 Musso G, Gambino R, Cassader M, et al. Meta-analysis: natural history of non-alcoholic fatty liver
25 13 disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity, *Ann Med*
26 14 2011;43:617-49.
- 27
28
29 15 6 Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty
30 16 liver disease: Practice Guideline by the American Association for the Study of Liver Diseases,
31 17 American College of Gastroenterology, and the American Gastroenterological Association,
32 18 *Hepatology* 2012;55:2005-23.
- 33
34
35 19 7 Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of
36 20 hepatic steatosis in the general population, *BMC Gastroenterol* 2006;6:33.
- 37
38 21 8 Fedchuk L, Nascimbeni F, Pais R, et al. Performance and limitations of steatosis biomarkers in
39 22 patients with nonalcoholic fatty liver disease, *Aliment Pharmacol Ther* 2014;40:1209-22.
- 40
41
42 23 9 Jung C, Lee W, Hwang J, et al. Assessment of the fatty liver index as an indicator of hepatic
43 24 steatosis for predicting incident diabetes independently of insulin resistance in a Korean
44 25 population, *Diabetic Med* 2013;30:428-35.
- 45
46
47 26 10 Onat A, Can G, Kaya A, et al. Fatty liver disease: Disparate predictive ability for cardiometabolic
48 27 risk and all-cause mortality, *World J Gastroenterol* 2015;21:13555-65.
- 49
50 28 11 Salonen JT. Is there a continuing need for longitudinal epidemiologic research? The Kuopio
51 29 Ischaemic Heart Disease Risk Factor Study, *Ann Clin Res* 1988;20:46-50.
- 52
53
54 30 12 Salonen JT, Seppanen K, Nyyssonen K, et al. Intake of mercury from fish, lipid peroxidation, and
55 31 the risk of myocardial infarction and coronary, cardiovascular, and any death in eastern Finnish
56 32 men, *Circulation* 1995;91:645-55.
- 57
58
59 33 13 Räsänen J, Kauhanen J, Lakka T, et al. Religious affiliation and all-cause mortality: a prospective
60 34 population study in middle-aged men in eastern Finland, *Int J Epidemiol* 1996;25:1244-9.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1 14 Laukkanen JA, Pukkala E, Rauramaa R, et al. Cardiorespiratory fitness, lifestyle factors and
2 cancer risk and mortality in Finnish men, *Eur J Cancer* 2010;46:355-63.
- 3 15 Willenbring ML, Massey SH, Gardner MB. Helping Patients Who Drink Too Much: An Evidence-
4 Based Guide for Primary Care Physicians. *Am Fam Physician* 2009;80.
- 5 16 McGuire S. U.S. Department of Agriculture and U.S. Department of Health and Human Services,
6 Dietary Guidelines for Americans, 2010. 7th Edition, Washington, DC: U.S. Government Printing
7 Office, January 2011, *Adv Nutr* 2011;2:293-4.
- 8 17 Fawehinmi TO, Ilomäki J, Voutilainen S, et al. Alcohol consumption and dietary patterns: the
9 FinDrink study, *PLoS One* 2012;7:e38607.
- 10 18 Virtanen JK, Mursu J, Tuomainen TP, et al. Dietary fatty acids and risk of coronary heart disease
11 in men: the Kuopio Ischemic Heart Disease Risk Factor Study, *Arterioscler Thromb Vasc Biol*
12 2014;34:2679-87.
- 13 19 Kauhanen J, Kaplan GA, Goldberg DE, et al. Pattern of alcohol drinking and progression of
14 atherosclerosis, *Arterioscler Thromb Vasc Biol* 1999;19:3001-6.
- 15 20 Alberti K. International Diabetes Federation Task Force on Epidemiology and Prevention;
16 National Heart, Lung, and Blood Institute; American Heart Association; Wo, *Circulation*
17 2009;120:1640-5.
- 18 21 Cheema JR. Some general guidelines for choosing missing data handling methods in educational
19 research, *Journal of Modern Applied Statistical Methods* 2014;13:3.
- 20 22 Jäger S, Jacobs S, Kröger J, et al. Association between the fatty liver index and risk of type 2
21 diabetes in the EPIC-Potsdam Study, *PLoS one* 2015;10:e0124749.
- 22 23 Nishi T, Babazono A, Maeda T, et al. Evaluation of the fatty liver index as a predictor for the
23 development of diabetes among insurance beneficiaries with prediabetes, *Journal of diabetes*
24 *investigation* 2015;6:309-16.
- 25 24 Balkau B, Lange C, Vol S, et al. Nine-year incident diabetes is predicted by fatty liver indices: the
26 French D.E.S.I.R. study, *BMC Gastroenterol* 2010;10:56,230X-10-56.
- 27 25 Shibata M, Kihara Y, Taguchi M, et al. Nonalcoholic fatty liver disease is a risk factor for type 2
28 diabetes in middle-aged Japanese men, *Diabetes Care* 2007;30:2940-4.
- 29 26 Bedogni G, Bellentani S. Fatty liver: how frequent is it and why, *Ann Hepatol* 2004;3:63-5.
- 30 27 Karajamaki AJ, Bloigu R, Kauma H, et al. Non-alcoholic fatty liver disease with and without
31 metabolic syndrome: Different long-term outcomes, *Metabolism-Clinical and Experimental*
32 2017;66:55-63.
- 33 28 Valenti L, Bugianesi E, Pajvani U, et al. Nonalcoholic fatty liver disease: cause or consequence of
34 type 2 diabetes? *Liver International* 2016;36:1563-79.

1
2
3 1 29 Targher G, Byrne CD. Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for
4 2 type 2 diabetes and its complications, *The Journal of Clinical Endocrinology & Metabolism*
5 3 2013;98:483-95.

7
8 4 30 Olubamwo OO, Virtanen JK, Voutilainen A, et al. Association of fatty liver index with the risk of
9 5 incident cardiovascular disease and acute myocardial infarction, *Eur J Gastroenterol Hepatol*
10 6 2018;30:1047-54.

12
13 7 31 Yang BL, Wu WC, Fang KC, et al. External validation of fatty liver index for identifying
14 8 ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan, *PLoS One*
15 9 2015;10:e0120443.

17 10
18 11
19 12
20 13
21 14
22 15
23 16
24 17
25 18
26 19
27 20
28 21
29 22
30 23
31 24
32 25
33 26
34 27
35 28
36 29
37 30
38 31
39 32
40 33
41 34
42 35
43 36
44 37
45 38
46 39
47 40
48 41
49 42
50 43
51 44
52 45
53 46
54 47
55 48
56 49
57 50
58 51
59 52
60 53

For peer review only

1
2
3 **APPENDIX**4
5 **Table 5 – Association of baseline fatty liver index with incident type 2 diabetes after excluding**
6 **smokers**
7

FLI	Number of subjects (% with T2D) (IR)	Model 1 HR (95% CI)	Model 2 HR (95% CI)
FLI*	1221(22.4) (11)	1.014(1.008-1.021)	1.016(1.009-1.022)
FLI category			
≤30 (Ref.)	549 (13.5) (7)	1.000	1.000
30-<60	380(23.9) (12)	1.43(1.02-1.99)	1.69(1.23-2.33)
≥60	292(37.0) (21)	2.24(1.54-3.26)	2.38(1.65-3.44)
P-trend	-	<0.001	<0.001

4 FLI – fatty liver index, FLI* - FLI uncategorized, HR – hazard ratio. CI – confidence interval. T2D – type 2 diabetes, IR –
5 Incidence rate per 1000 person-years

6 Model 1: FLI, age, examination date, family history of diabetes, alcohol consumption per week, physical activity, fruit-
7 berry-vegetable consumption, C-reactive protein, leukocytes albumin, fibrinogen, and ferritin, systolic blood pressure,
8 diastolic blood pressure, insulin, fasting glucose, LDL, and HDL.

9 Model 2: FLI, age, examination date, family history of diabetes, alcohol consumption per week, physical activity, fruit-
10 berry-vegetable consumption, C-reactive protein, leukocytes albumin, fibrinogen, and ferritin, metabolic syndrome
11 status.

12 ^a Other independent predictors of T2D in the model were family history of diabetes, serum ferritin, alcohol
13 consumption, and fasting glucose.

14 ^b Other independent predictors of T2D in the model were family history of diabetes, serum ferritin, alcohol
15 consumption, and metabolic syndrome status. HR metabolic syndrome = 1.76(1.28-2.41).

16

BMJ Open

Association of Fatty Liver Index with risk of Incident Type 2 Diabetes by Metabolic Syndrome Status in an Eastern Finland Male Cohort - a Prospective Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026949.R2
Article Type:	Research
Date Submitted by the Author:	30-May-2019
Complete List of Authors:	Olubamwo, Olubunmi; Ita-Suomen yliopisto Terveystieteiden tiedekunta, Public Health and Clinical Nutrition Virtanen, Jyrki K.; Ita-Suomen yliopisto Kansanterveystiede ja kliininen ravitsemustiede, Public Health and Clinical Nutrition Pihlajamaki, Jussi; University of Eastern Finland School of Medicine, Public health and clinical nutrition; Clinical nutrition and obesity center, Kuopio university hospital, Kys, Kuopio, Tuomainen, Tomi-Pekka; Ita-Suomen yliopisto Kansanterveystiede ja kliininen ravitsemustiede, Public Health and Clinical Nutrition
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Gastroenterology and hepatology, Public health
Keywords:	EPIDEMIOLOGY, Hepatology < INTERNAL MEDICINE, Diabetes & endocrinology < INTERNAL MEDICINE, PREVENTIVE MEDICINE, PUBLIC HEALTH

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Association of Fatty Liver Index with risk of Incident Type 2 Diabetes by Metabolic Syndrome**
2 **Status in an Eastern Finland Male Cohort – A Prospective Study**

3 Olubunmi O. Olubamwo¹, Jyrki K. Virtanen¹, Jussi Pihlajamäki^{1,2}, Tomi-Pekka Tuomainen¹

4
5
6
7
8
9 ¹ Institute of Public Health and Clinical Nutrition, Faculty of Health Sciences, University of Eastern
10 Finland, Kuopio, Finland.

11 ² Clinical Nutrition and Obesity Center, Kuopio University Hospital, KYS Kuopio, Finland.

12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Running head: FLI and risk of T2D by MS status. Olubamwo et al.

Word count: main text 3897 words, abstract 288 words.

For peer review only

*Corresponding author:

Olubunmi O, Olubamwo
Institute of Public Health and Clinical Nutrition
Faculty of Health Sciences
University of Eastern Finland, Kuopio,
P.O.Box 1627, FI-70211 Kuopio, Finland.
E-mail : olubunmi.olubamwo@uef.fi Tel : +358 403552905.

1 ABSTRACT

2 **Objective:** Fatty liver disease (FLD) is increasingly recognized as a predictor of cardiometabolic
3 risk. Our objective was to examine if metabolic syndrome (MS) status affects the association of
4 FLD with incident Type-2 diabetes (T2D) in middle-aged men.

5 **Design:** Prospective epidemiological study.

6 **Setting:** University affiliated research center in Kuopio, Eastern Finland.

7 **Participants:** our subjects were 1792 Finnish men without diabetes at baseline in the Kuopio
8 Ischaemic Heart Disease Risk Factor Study (KIHD) cohort.

9 **Outcome Measure:** Using fatty liver index (FLI), the association of baseline FLD with incident T2D
10 was analyzed in multivariable-adjusted Cox regression models, considering their MS statuses. The
11 main models were adjusted for constitutional factors, lifestyle factors, biomarkers of inflammation
12 and for high (FLI \geq 60) vs low (FLI $<$ 30) FLI categories.

13 **Results:** During a mean follow-up of 19 years, 375 incident cases of T2D were recorded. In the full
14 model, the hazard ratio (HR (95%CI)) for T2D was 3.68(2.80-4.82). The association was attenuated,
15 but maintained, with further adjustment for metabolic factors. When MS status was adjusted for in
16 place of metabolic factors, the HRs (95%CI) were 2.63(1.92-3.59) for FLI \geq 60 and 1.77(1.35-2.31) for
17 MS.

18 In MS-stratified analysis, FLI predicted T2D only among persons without MS. In unstratified analysis
19 with subjects categorized by FLI-MS, persons with FLI \geq 60 without MS had increased risk for T2D
20 (HR= 3.19(2.26-4.52)) compared with persons with FLI $<$ 30 without MS. Persons with FLI $<$ 30 and MS
21 had greater risk (HR= 4.31(2.15-8.61)) and, persons with both FLI \geq 60 and MS had the greatest risk
22 (HR=4.66(3.42-6.35)).

1
2
3 1 **Conclusion:** Generally, FLD (FLI \geq 60) predicts T2D. It specifically predicted T2D among men without
4
5 2 MS but not among men with MS, for whom MS alone already increases the risk. Both FLI and MS
6
7
8 3 can complement each other in screening and surveillance for persons with increased T2D risk.
9

10 4
11
12
13 5 **KEY WORDS:** fatty liver index, fatty liver disease, type 2 diabetes, metabolic syndrome, predictor,
14
15
16 6 metabolic factors, Kuopio Ischaemic Heart Disease Risk Factor Study
17
18
19 7

22 8 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- 25 9 • The study is population-based and the design is prospective, with long follow-up.
- 27 10 • We adjusted for a range of constitutional factors, lifestyle factors and biomarkers keeping
28
29 11 in cognizance the components of both major exposure variables to avoid overadjustment.
- 32 12 • The study population comprised of men only.
- 35 13 • Fatty Liver Index used as a surrogate of fatty liver does not detect progression of fatty liver
36
37 14 disease.
- 40 15 • The statuses of the men with respect to viral hepatitis were not established at baseline,
41
42 16 although, viral hepatitis have remained low in the Finnish population.

1 INTRODUCTION / BACKGROUND

2 There is increasing recognition of the fact that fatty liver disease (FLD) is the commonest cause of
3 chronic liver disease worldwide. Also known as hepatic steatosis, FLD is associated with increased
4 risk of cardiovascular disease (CVD) and Type 2 diabetes (T2D). The prevalence has been observed
5 to steadily rise; although, this varies in different populations. Recent estimates suggest a global
6 prevalence of 25% among adults, but the highest prevalence occurs in the Middle East and South
7 America while the lowest prevalence is in Africa [1]. The prevalence is estimated to be 24% in Europe
8 and more than 30% in developed countries [1]. Approximately one third of FLD patients progress to
9 steatohepatitis with fibrosis, which can thereafter progress to cirrhosis, liver failure and
10 hepatocellular carcinoma [1]. Fatty Liver Disease is intimately linked with metabolic diseases,
11 including T2D and, it can be considered a predictor of metabolic diseases, even in the non-obese
12 population [2].

13 While FLD is an acknowledged public health problem, there is growing interest in FLD as a predictor
14 of incident T2D [3]. A number of epidemiological studies suggest that non-alcoholic fatty liver
15 disease (NAFLD), diagnosed using either liver enzymes or ultrasound scan (USS), is associated with
16 an increase in T2D incidence [4, 5].

17 Liver biopsy is the gold standard for characterizing liver histology in patients with fatty liver. The
18 procedure is expensive and carries some morbidity and very rare mortality risks [6]. The fatty liver
19 index (FLI), an algorithm comprising of body mass index, waist circumference, gamma-glutamyl
20 transferase (GGT) and triglyceride concentrations. It was developed by Bedogni et al., to predict
21 the presence of FLD. The algorithm has been widely validated, and has gained increased
22 acceptance [7, 8]. There have been reports of an association of high FLI (FLD) with incident T2D
23 [9], [10]. However, with FLD being intimately linked with metabolic diseases, it is uncertain

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 whether the predictive ability of FLD is independent of presence of established metabolic
2 syndrome (MS), a known potent predictor of T2D.
3 Therefore, using FLI as a surrogate for FLD, we examined whether MS status affects the association
4 of FLD, with incident T2D in middle-aged men.

For peer review only

1 METHODS

2
3
4
5
6 **Study population:** Our study population comprised participants in the Kuopio Ischaemic Heart
7
8 Disease Risk Factor Study (KIHD). The KIHD study is a prospective population-based study. It was
9
10 designed to investigate risk factors for CVDs and related outcomes, in middle-aged and ageing men,
11
12 from Eastern Finland. The original study population consisted of an age-stratified sample of 2682
13
14 men. These were enrolled at baseline between March 1984 and December 1989. The men were 42,
15
16 48, 54, or 60 years of age at baseline. The study was approved by the Research Ethics Committee of
17
18 the University of Kuopio [11], and the subjects gave their written consent.
19
20
21
22

23
24 **Data Collection:** Data were collected using self-administered questionnaires, interviews, physical
25
26 examinations, and various blood tests which aimed to elucidate physiological and biochemical
27
28 parameters [12, 13]. The self-administered questionnaire was used to collect data on medical
29
30 history, including history of type 2 diabetes, metabolic diseases, liver disease, etc., medication
31
32 history, family history of diabetes, and family history of CVD[12]. Data on lifestyle, including physical
33
34 activity, history of smoking habit, history of alcohol consumption, and diet, were also collected [14].
35
36 Categorisation of alcohol consumption was done according to standard guidelines by the National
37
38 Institute of Alcohol Abuse and Alcoholism [15] and Dietary Guidelines for Americans 2010 [16] as
39
40 already published [17].
41
42
43
44
45

46 A family history of CVD or diabetes was defined as positive if the father, mother, sister, or brother
47
48 of the subject had a history of CVD or diabetes. [12]. A subject was defined as a smoker if he had
49
50 ever smoked on a regular basis and had smoked cigarettes, cigars, or pipe within the previous 30
51
52 days. Dietary intakes including fruit, berry and vegetable consumption were assessed with a 4-day
53
54 food recording [18].
55
56
57
58
59
60

1
2
3 1 Physical examinations included anthropometric indices, vital signs, and physiologic measurements.
4
5
6 2 All measurements were made following standard protocols. Waist circumference was calculated as
7
8 3 the mean of waist circumferences taken at maximal inspiration and maximal expiration. Body mass
9
10 4 index (BMI) was computed as the ratio of weight in Kg to the square of height in meters (kg/m²).
11
12
13 5 Blood pressure, was taken as the mean of measurements taken in the supine, standing and sitting
14
15 6 position with 5-minute intervals [19].
16
17

18 7 **Specimen collection and laboratory measurements-** Blood samples were collected between 08.00
19
20 8 and 10.00 hours after 3 days of abstinence from alcohol ingestion and a 12-hour abstinence from
21
22 9 smoking and eating. Data on complete blood count, serum electrolytes, Homeostatic model
23
24 10 assessment of insulin resistance (HOMA1-IR), fasting glucose, lipoprotein fractions (including total
25
26 11 cholesterol, HDL cholesterol, LDL cholesterol, serum triglycerides), liver function tests including
27
28 12 albumin, gamma-glutamyl transferase, fibrinogen, ferritin, and biomarkers like C-reactive protein
29
30 13 (CRP), were each determined from appropriately collected and processed samples. Detailed
31
32 14 description of the KIHD has been published elsewhere [11].
33
34
35
36
37

38 15 **Included and excluded subjects:** The initial number of men at baseline was 2682. Of these, we
39
40 16 excluded 40 men with history of physician diagnosed liver or pancreas disease, and 162 men with
41
42 17 history of diabetes. Of the remaining 2480 men, 1792 who had complete data for FLI calculation,
43
44 18 were included in the analyses.
45
46
47

48 19 **Measuring the components of the Fatty liver index:** We calculated FLI using the algorithm
49
50 20 developed by Bedogni et al [7]. The algorithm, incorporates four variables: BMI, waist
51
52 21 circumference, serum triglycerides, and serum gamma-glutamyl transferase (GGT), and is expressed
53
54 22 as follows:
55
56
57
58
59
60

$$FLI = \frac{(e^{0.953 \times \ln(\text{triglycerides}) + 0.139 \times \text{BMI} + 0.718 \times \ln(\text{ggT}) + 0.053 \times \text{waist circumference} - 15.745})}{(1 + e^{0.953 \times \ln(\text{triglycerides}) + 0.139 \times \text{BMI} + 0.718 \times \ln(\text{ggT}) + 0.053 \times \text{waist circumference} - 15.745})} \times 100$$

Where triglycerides is in mg/dl, waist circumference in cm, and BMI in Kg/m². We categorized FLI in accordance with Bedogni's categorization, as low FLI (<30), intermediate FLI (30-<60), and moderate-high FLI (>60), indicating no fatty liver, indeterminate, and fatty liver, respectively.

Defining Metabolic Syndrome Status: MS was defined in accordance with the harmonized criteria for diagnosis of MS [20]. The presence of any three of the following five risk factors constitutes a diagnosis of metabolic syndrome: waist circumference ≥ 120 cm; serum triglycerides ≥ 150 mg/dL (1.7 mmol/L) (or drug treatment for elevated triglycerides); HDL cholesterol < 40 mg/dL (1.0 mmol/L) (or drug treatment for reduced HDL cholesterol); blood pressure with systolic ≥ 130 and/or diastolic ≥ 85 mm Hg (or antihypertensive drug treatment in a patient with a history of hypertension); fasting glucose ≥ 100 mg/dl (or drug treatment of elevated glucose), [20].

Outcome Definitions: We defined incident T2D outcomes as self-reported physician-set diagnosis of T2D and/or; fasting plasma glucose ≥ 7.0 mmol/L or 2-h oral glucose tolerance test plasma glucose ≥ 11.1 mmol/L at re-examination rounds 4, 11, and 20 years after the baseline and; T2D information derived by record linkage to either the national hospital discharge registers or to the Social Insurance Institution of Finland register for reimbursement of medicine expenses used for T2D. Detection of T2D by self-report of physician diagnosed T2D was followed by either detection via the hospital discharge registers or National drug reimbursement register. The proportion of the data obtained by the record linkage are as follows: hospital discharge registers 42%, and National drug reimbursement register 58%. T2D cases that were included were those coded in the Tenth International Classification of Diseases (ICD 10 code numbers from E11.0 to E11.9).

1
2
3 1 **Patient and public involvement:** The study was carried out in a non-patient research facility. All the
4
5
6 2 study participants were volunteers. Neither the study participants nor the public were involved in
7
8 3 the design of the study.
9

10
11 4
12
13 5 **Statistical Methods:** All statistical analyses were performed using SPSS software Version 21.0 for
14
15
16 6 Windows (IBM, Chicago, IL). In all analyses, two-sided alpha <0.05 was considered statistically
17
18 7 significant.
19

20
21 8 Descriptive analyses were performed to summarise baseline characteristics of participants
22
23 9 according to baseline FLI categories. For continuous variables, we used Jonckheere trend test to test
24
25
26 10 for linear trend across FLI categories. For categorical variables, we used Chi-Square test to test for
27
28 11 linear association across FLI categories. To make up for missing 0.4% values (spread across 50% of
29
30
31 12 the variables and 13.4% of subjects), we used a regression based multiple imputation method (40
32
33 13 iterations) according to guideline by Cheema 2014 [21].
34

35
36 14 After confirmation of proportionality of hazards, we implemented a multivariable-adjusted Cox
37
38
39 15 proportional hazards model, to examine the relationship between baseline FLI and incident T2D
40
41 16 considering metabolic factors and the MS statuses of the subjects as follows:
42

43
44 17 First, we analyzed the overall association, adjusting for MS status. The models were as follows:
45
46
47 18 model 1- Examination year, constitutional factors (age and family history of T2D), lifestyle factors
48
49 19 (smoking pack years, alcohol consumption, physical activity and, consumption of fruits, berries and
50
51 20 vegetables) and, inflammatory markers (C-reactive protein, leukocyte count, thrombocyte count),
52
53
54 21 and metabolic factors (fasting glucose, insulin, HDL, LDL, systolic blood pressure, diastolic blood
55
56 22 pressure); model 2- Examination year, constitutional factors (age and family history of T2D), lifestyle
57
58
59 23 factors (smoking pack years, alcohol consumption, physical activity and, consumption of fruits,
60

1
2
3 1 berries and vegetables) and, inflammatory markers (C-reactive protein, leukocyte count,
4
5
6 2 thrombocyte count), and MS status.

7
8
9 3 In sensitivity analyses, we excluded men with a high weekly alcohol consumption of ≥ 168 g [17]
10
11 4 before analyzing the overall association of FLI with T2D in multivariable adjusted Cox proportional
12
13 5 hazards as explained above. In addition, we excluded smokers before analyzing the overall
14
15
16 6 association of FLI with T2D in multivariable adjusted Cox proportional hazards.

17
18
19 7 Secondly, we performed sub-group analyses in which we stratified our study sample by MS status.
20
21 8 We then performed multivariable-adjusted Cox proportional hazards analysis with adjustment for
22
23 9 covariates to observe if the association of FLI with incident T2D differs by MS status in model 1 and
24
25
26 10 2 as explained above, but excluding fasting glucose in model 2.

27
28
29 11 Thirdly, for clearer understanding of the relation of the associations considering both FL and MS
30
31 12 statuses, using the combination of FLI category and MS status as a composite variable, we
32
33 13 performed multivariable-adjusted Cox proportional hazards analysis on the study population with
34
35 14 adjustment for covariates as in model 1 above, to elaborate the variation of the association by MS
36
37
38
39 15 status.

1 RESULTS

2
3
4
5
6 2 **Characteristics of the study population:** The baseline characteristics of the study population (1792
7
8
9 3 men) according to FLI categories are shown in Table 1. In general, the mean values and proportions
10
11 4 for men in the intermediate FLI category were in between estimates for the lowest (reference) FLI
12
13
14 5 category and estimates for the highest FLI category. Compared with the low FLI category, the high
15
16 6 FLI category had a greater proportion of men with family history of diabetes, and a greater
17
18
19 7 proportion with family history of CVD. Men in the high FLI category consumed less fruit, berries and
20
21 8 vegetables, and more likely to be heavy alcohol consumers. They had higher mean waist
22
23
24 9 circumference and mean BMI and they were more likely to be hypertensive. They also had higher
25
26 10 GGT levels, higher triglyceride, higher fasting insulin, higher blood glucose, lower HDL cholesterol
27
28
29 11 and higher levels of markers of systemic inflammation. Generally, the range of values of the fasting
30
31 12 blood glucose for the eligible men was between 3.1 mmol/l (minimum) and 6.2 mmol/l (or 112
32
33 13 mg/dl) (maximum).

34
35
36 14 **Multivariable proportional hazards model analyses:** During a mean (SD) follow-up of 18.8(6.6)
37
38
39 15 years, there were 375 cases of incident T2D. The incidence rate for T2D was 11 cases per 1000
40
41 16 person-years. Significantly lower survival free of incident T2D was noted for participants in high
42
43
44 17 baseline FLI category compared to the low (normal) FLI category at baseline (Log-rank < 0.001).
45
46 18 Subjects in intermediate FLI category also separated clearly from those with Low FLI for incident
47
48
49 19 T2D.

20 **Relation between baseline Fatty Liver Index and incident T2D**

51
52
53
54 21 **Overall analyses:** Table 2 shows the association of FLI with incident T2D. In model 1, the HRs for
55
56
57 22 incident T2D was 42% higher for the intermediate category, and 113% higher for the high FLI
58
59 23 category, when compared with the low category. The association was maintained, in model 2 with
60

1 MS where high FLI category was associated with 163% increased risk. MS was also independently
2 associated with incident T2D in the model, with 77% increased risk (HR (95%CI) 1.77(1.35-2.31)).

3 *Sensitivity analyses* - after exclusion of 241 men who were heavy alcohol consumers (Table 3), the
4 results were similar to those obtained in the analyses with the whole sample, as shown in Table 2.

5 Similarly, after exclusion of 571 men who were smokers (Appendix), the results were similar to those
6 obtained in the analyses with the whole sample, as shown in Table 1 of the appendix.

7 Further exploration of the association of FLI with incident T2D across FLI categories of 10 (see Figure
8 1) reveals steady increase in HR across the categories without any threshold areas. When we
9 analyzed our data with FLI as continuous variable, a unit increase in FLI was associated with 1.7%
10 increase in HR (in the analyses with the whole sample), and 1.8% increase (after exclusion heavy
11 alcohol consumers), as shown in Tables 2 and 3.

12 **Stratified analyses:** Table 4 shows the results of Cox regression analysis when we stratified by MS
13 status. In the stratus without MS, high FLI was associated with over 100% increased risk of T2D when
14 compared with those in the low FLI category. Among those with MS, high FLI was not associated
15 with additional risk when compared with those in the low FLI category.

16 **Analysis with composite FLI-MS variable:** In additional sensitivity analyses, with the combination of
17 FLI category and MS status as composite exposure variable, when compared with subjects having
18 neither fatty liver nor MS, having high FLI with no MS was associated with 219% increase in risk (the
19 HR (95%CI) was 3.19(2.26-4.51)). Having normal FLI with MS was associated with 331% increased
20 risk (the HR (95%CI) was 4.31(2.15-8.61)) and, persons having high FLI and MS were at greatest risk,
21 with 366% increase in risk (HR (95%CI) 4.66(3.42-6.35)). The presence of MS was associated with
22 greater risk in intermediate and high FLI categories (the HRs (95%CI) were 3.77(2.50-5.70) for
23 presence of MS with intermediate FLI category, and 4.66(3.42-6.35) for the presence of MS with
24 high FLI category).

1 **Table 1 - Baseline characteristics of 1792 men according to fatty liver index (FLI) categories**

Characteristic	FLI<30	FLI=30-< 60	FLI≥60	P-trend*
	Mean (SD)	Mean (SD)	Mean (SD)	
	or n (%)	or n (%)	or n (%)	
	N=833	N=552	N=407	
FLI	16.2 (7.7)	43.3 (8.1)	76.8 (10.6)	<0.001
Constitutional factors				
Age in years	52.6 (5.6)	53.4 (5.5)	52.5 (5.6)	0.251
Family history of diabetes	212 (25.5%)	145 (27.8%)	108 (26.5%)	0.651
Family history of CVD	667 (80.1%)	459 (83.2%)	341 (83.8%)	0.072
Lifestyle factors				
Smoking pack years	7.5(16.0)	8.4(16.8)	6.8(13.6)	0.785
Alcohol consumption (g/week)	55 (89)	78 (117)	116 (165)	<0.001
Physical activity (Energy exp.) (kcal/day)	136(156)	147(175)	129(192)	0.36
Fruit, berry and vegetable consumption (g/day)	265 (171)	261 (148)	233 (147)	0.023
Anthropometrics and physiologic measurements				

Mean waist circumference (cm)	83.9 (6.1)	92.7 (5.2)	101.8 (8.1)	<0.001
BMI (kg/m ²)	24.4 (2.0)	27.3 (1.9)	30.7 (3.1)	<0.001
Mean systolic bp	135.5(17.0)	135.7(17.8)	135.9(18.1)	<0.001
Mean diastolic bp	89.4(10.5)	88.5(10.6)	89.6(11.1)	<0.001
Hypertension	259 (31.1%)	275 (49.8%)	261 (64.1%)	<0.001
Biomarkers				
Insulin	8.3 (3.0)	11.2 (4.4)	16.6 (9.7)	<0.001
Glucose (mmol/L)	4.5 (0.4)	4.6 (0.5)	4.8 (0.5)	<0.001
HOMA1-IR insulin resistance	1.86 (0.71)	2.60 (1.10)	3.91 (2.30)	<0.001
Total cholesterol (mmol/L)	5.71 (1.07)	5.93 (1.02)	6.05 (1.00)	<0.001
HDL cholesterol (mmol/L)	1.38 (0.32)	1.25 (0.26)	1.20 (0.27)	<0.001
LDL cholesterol (mmol/L)	3.91 (1.01)	4.09 (0.97)	4.01 (0.93)	0.04
Triglycerides (mmol/L)	0.94 (0.40)	1.35 (0.62)	1.93 (1.02)	<0.001
Gamma-glutamyl transferase (U/L)	18 (11)	28 (20)	51 (47)	<0.001
Albumin	42 (4)	42 (4)	43 (3)	<0.001
C- reactive protein (m/L)	1.86 (4.46)	2.61 (4.54)	3.15 (4.26)	<0.001
Ferritin (µg/L)	128 (100)	172 (157)	235 (186)	<0.001

Fibrinogen g/L	2.92 (0.58)	3.06 (0.57)	3.10 (0.55)	<0.001
Leukocyte count x10 ⁹ /L	5.4 (1.6)	5.7 (1.6)	5.9 (1.6)	<0.001
Metabolic syndrome and medication use history				
Metabolic syndrome	29 (3.5%)	91 (16.5%)	238 (58.5%)	<0.001
Drug for high cholesterol	7 (0.84%)	2 (0.36%)	6 (1.47%)	0.509
Drug for hypertension	111 (13.32%)	127 (23.05%)	141(34.56%)	<0.001

*Jonckheere trend test for continuous variable. Chi-Square linear-by-linear association for categorical variables. bp- blood pressure

1 DIABETES PREDICTION

2 **Table 2 – General association of baseline fatty liver index (FLI) with incident type 2 diabetes**

FLI	Number of subjects (%) with T2D (IR)	Model 1 HR (95% CI)	Model 2 HR (95% CI)
FLI*	1792 (20.9) (11)	1.013(1.007-1.018) ^a	1.017(1.012-1.022) ^b
FLI category			
≤30 (Ref.)	833 (12.1) (6)	1.000	1.000
30-<60	552 (22.6) (12)	1.42(1.07-1.88)	1.81(1.38-2.37)
≥60	407 (36.6) (22)	2.13(1.56-2.93) ^a	2.63(1.92-3.59) ^b
P-trend	-	<0.001	<0.001

3 *FLI uncategorized, HR – hazard ratio. CI – confidence interval. T2D – type 2 diabetes, IR – Incidence rate per 1000 person-years

4 Model 1: FLI, age, examination date, family history of diabetes, smoking pack years, alcohol consumption per week, physical activity, fruit-berry-vegetable consumption, C-reactive protein, leukocytes albumin, fibrinogen, and ferritin, systolic blood pressure, diastolic blood pressure, insulin, fasting glucose, LDL, and HDL.

5 Model 2: FLI, age, examination date, family history of diabetes, smoking pack years, alcohol consumption per week, physical activity, fruit-berry-vegetable consumption, C-reactive protein, leukocytes albumin, fibrinogen, and ferritin, and metabolic syndrome status.

6 ^a Other independent predictors of T2D in the model were family history of diabetes, serum ferritin, hypertension, serum insulin, and glucose.

7 ^b Other independent predictors of T2D in the model were family history of diabetes, serum ferritin and metabolic syndrome status. HR metabolic syndrome = 1.77(1.35-2.31).

Table 3 – Association of baseline fatty liver index with incident type 2 diabetes after excluding men with high alcohol intake

FLI	Number of subjects (% with T2D) (IR)	Model 1 HR (95% CI)	Model 2 HR (95% CI)
FLI*	1548(20.9) (11)	1.014(1.008-1.019)	1.018(1.012-1.024)
FLI category			
≤30 (Ref.)	771(12.5) (6)	1.000	1.000
30-<60	472(23.1) (12)	1.43(1.06-1.93)	1.78(1.33-2.37)
≥60	305(38.7) (23)	2.21(1.57-3.10)	2.63(1.89-3.66)
P-trend	-	<0.001	<0.001

FLI – fatty liver index, FLI* - FLI uncategorized, HR – hazard ratio. CI – confidence interval. T2D – type 2 diabetes, IR – Incidence rate per 1000 person-years

Model 1: FLI, age, examination date, family history of diabetes, smoking pack years, alcohol consumption per week, physical activity, fruit-berry-vegetable consumption, C-reactive protein, leukocytes albumin, fibrinogen, and ferritin, systolic blood pressure, diastolic blood pressure, insulin, fasting glucose, LDL, and HDL.

Model 2: FLI, age, examination date, family history of diabetes, smoking pack years, alcohol consumption per week, physical activity, fruit-berry-vegetable consumption, C-reactive protein, leukocytes albumin, fibrinogen, and ferritin, and metabolic syndrome status.^a Other independent predictors of T2D in the model were family history of diabetes, serum ferritin, hypertension, serum insulin, and fasting glucose.

^b Other independent predictors of T2D in the model were family history of diabetes, serum ferritin and metabolic syndrome status. HR metabolic syndrome = 1.65(1.24-2.21).

1
2
3 **Table 4 – Association of fatty liver index (FLI) with incident type 2 diabetes by metabolic**
4 **syndrome status (sub-analyses)**
5

No metabolic syndrome	Number of subjects (% with T2D) (IR)	Model 1 HR(95%CI)	Model 2 HR(95%CI)
FLI*	1427(16.7) (9)	1.021 (1.015-1.027)	1.017 (1.010-1.025) ^a
FLI category			
≤30 (Ref.)	803(11.5) (6)	1.00	1.00 ^b
30-<60	456(20.0) (11)	1.81(1.33-2.46)	1.58(1.14-2.19)
≥60	168(33.3) (18)	3.07(2.14-4.41)	2.38(1.58-3.58)
p-trend		<0.001	<0.001
Metabolic syndrome	Number of subjects (% with T2D) (IR)	Model 1 HR(95%CI)	Model 2 HR(95%CI)
FLI*	358(37.7)(24)	1.007(0.997-1.016)	0.996(0.992-1.000) ^c
FLI category			
≤30 (Ref.)	29(31.0) (23)	1.000	1.000 ^d
30-<60	91(36.3) (21)	0.77(0.35-1.70)	0.80(0.59-1.09)
≥60	238(39.1) (25)	1.02(0.49-2.16)	0.79 (0.58-1.06)
p-trend		0.42	0.22
Category by FLI and MS status	Number of subjects (% with T2D) (IR)	Model 1 HR(95%CI)	
FLI≤30 MS ⁻	803(11.5) (6)	1.000	-
FLI30-<60MS ⁻	456(20.0) (11)	1.79(1.33-2.41)	-

FLI \geq 60MS ⁻	168(33.3) (18)	3.19(2.26-4.51)	-
FLI \leq 30 MS ⁺	29(31.0) (23)	4.31(2.15-8.61)	-
FLI30-<60MS ⁺	91(36.3) (21)	3.77(2.50-5.70)	-
FLI \geq 60MS ⁺	238(39.1) (25)	4.66(3.42-6.35)	-

*FLI uncategorized, Ref – reference. HR – hazard ratio. CI – confidence interval. T2D – type 2 diabetes, IR – Incidence rate per 1000 person-years

*Statistically significant at $P \leq 0.05$. MS – Metabolic syndrome. MS⁻ - Metabolic syndrome negative. MS⁺ - Metabolic syndrome positive.

Model 1: FLI, age, examination date, family history of diabetes, smoking pack years, alcohol consumption per week, physical activity, fruit-berry-vegetable consumption, C-reactive protein, leukocytes, thrombocytes, fibrinogen, and ferritin.

Model 2: Model 1 plus systolic blood pressure, diastolic blood pressure, insulin, LDL, and HDL

^a Other independent predictors of T2D in the model were serum ferritin and insulin.

^b Other independent predictors of T2D in the model were serum ferritin and insulin.

^c Independent predictors of T2D in the model were fasting glucose and insulin.

^d Independent predictors of T2D in the model were fasting glucose and insulin.

Figure 1 – Graph of FLI and risk of incident T2D.

1 DISCUSSION

2 We examined the association of FLI, a surrogate of fatty liver disease, in relation to incident T2D in
3 a population of middle-aged men, while taking the baseline MS status into account. We found that
4 although FLD assessed by FLI predicts the risk of T2D in the study population, the association was
5 strongest among persons without MS at baseline.

6 Few studies have investigated the association of baseline FLI as categorized by Bedogni et al., with
7 incident T2D [10, 22]. Jager et al.[22] and Onat et al. [10], studied the association of FLI with incident
8 T2D in healthy populations, followed up for eight years. Nishi et al.[23], studied the association of
9 FLI with incident T2D in a population of prediabetic subjects followed up for three years[23].

10 A few studies, Balkau et al.[24] and Jung et al.[9] also reported the association of FLI with incident
11 T2D using FLI categorization different from that proposed by Bedogni et al. [9, 24]. Because previous
12 studies on the association of FLI with incident T2D have adjusted for different groups of variables in
13 their multivariable models, we are careful in our comparison of findings.

14 Our finding that high FLI (FLI \geq 60) indicating fatty liver, is associated with increased risk independent
15 of constitutional and lifestyle factors, agrees with findings from previous findings by Jager et al.[22]
16 and Onat et al.[10]. We found a 2 to 3-fold increased risk in our multivariable adjusted models.
17 However, Jager et al., reported 11-fold increase while Onat et al reported a 5-fold increase. Our
18 finding, that intermediate FLI is also associated with increased risk of T2D, is also in line with reports
19 by Jager et al.

20 Our finding that high FLI is associated with incident T2D even after adjusting for metabolic factors,
21 agrees with other reports.[10],[24] [9], each of which used different cut-off points in categorizing
22 FLI. Balkau et al. used FLI <20 and FLI \geq 70 as lower and upper cut-off points, and adjusted for glucose,
23 insulin, and hypertension. Jung et al, used FLI<20 and FLI \geq 60 as lower and upper cut-off points.

1
2
3 1 When we re-analyzed our data using these cut-off points, the results (data not shown) did not differ
4
5 2 markedly from what we present here.
6
7

8
9 3 Indeed, ultrasound diagnosed NAFLD has been shown to be associated with incident T2D and, the
10
11 4 association is not affected by adjustment for metabolic syndrome [5]. However, the predictability
12
13 5 of T2D independent of MS using FLI needs to be clarified.
14
15

16 6 We are unable to compare our findings on association of FLI with incident T2D in view of MS status
17
18 7 of the subjects, with previous studies on the association between FLI and incident T2D because
19
20 8 previous studies on the association did not consider the MS status of the subjects. However, this
21
22 9 finding corroborates the report by Shibata et al. [25]. Shibata et al. found that the presence of fatty
23
24 10 liver, as diagnosed by ultrasonography, is associated with increased risk of T2D when compared with
25
26 11 those without fatty liver after adjusting for age, BMI, smoking status, physical activity, and MS status
27
28 12 [25].
29
30
31
32

33 13 The finding of similar results, after excluding men who were heavy consumers of alcohol, indicates
34
35 14 that our findings are also applicable to NAFLD. However, despite the multifactorial nature of the
36
37 15 aetiology of FLD, the relative contribution of heavy ethanol intake in the pathogenesis of fatty liver
38
39 16 is still uncertain [26]. Therefore, we did not exclude men with high alcohol intake in our main
40
41 17 analysis. The finding of similar results after excluding smokers proves further that smoking is not a
42
43 18 confounder in this target population.
44
45
46
47

48 19 Stratification by MS status did not reveal significant association of high FLI with incident T2D in
49
50 20 subjects with MS, despite the fact that increasing proportions of subjects with MS developed T2D
51
52 21 across the FLI categories. This suggests that among persons with MS, which is already a cluster of
53
54 22 risk factors for T2D (including hyperglycaemia), high FLI is likely not associated with significantly
55
56 23 higher risk than that due to positive MS status alone. It also suggests that the MS status was an
57
58 24 effect modifier in the overall analysis.
59
60

1
2
3 1 Notwithstanding, our findings from the analysis with FLI-MS composite variable, are noteworthy. It
4
5
6 2 appears that FLI predicts risk of T2D in a dose-dependent manner among subjects without MS but
7
8 3 among subjects with MS, it does not predict risk of T2D in a dose-dependent manner. The additional
9
10 4 risk associated with high FLI appears less than that associated with MS positive status. Therefore,
11
12
13 5 the greatest risk was in subjects with both fatty liver and MS positivity. Our finding that the presence
14
15 6 of MS appears to be associated with higher risks than high FLI, may be consistent with the finding
16
17
18 7 by Käräjämäki et al [27]. However, Käräjämäki et al, observed from their data that, in the absence
19
20 8 of MS, fatty liver does not tend to pose a higher risk for development of T2D in comparison to
21
22
23 9 healthy subjects [27]. Our finding that, compared with healthy subjects (persons with normal FLI
24
25 10 and no MS), persons having high FLI and negative MS status were at increased risk, disagrees with
26
27
28 11 their observation.

29
30 12 Comparison of risks with FLI<10 as the reference reveals steady increase in risk across FLI (Figure 1).
31
32
33 13 This supports the suggestion that, even among subjects with intermediate FLI, the risk of incident
34
35 14 T2D increases with increasing FLI values.

36
37 15 Our findings can be explained in the light of current knowledge. It is thought that an initial
38
39
40 16 development of insulin resistance results in compensatory hyperinsulinemia and, together with
41
42 17 visceral obesity, promotes the development of FLD [28]. In return, the insulin resistant fatty liver
43
44
45 18 overproduces glucose and very low-density lipoprotein. This boosts mechanisms that lead to
46
47 19 exhaustion of pancreatic beta cell reserve, eventually leading to the development of T2D [28].
48
49
50 20 Steatotic and inflamed liver secretes hepatokines such as fetuin-A, fetuin-B, angiotensin-like
51
52 21 proteins, fibroblast growth factor 21, and selenoprotein P, that have endocrine function at
53
54
55 22 extrahepatic sites to cause insulin resistance and other adverse effects on glucose homeostasis [29].
56
57 23 Hence, the association of high FLI with T2D.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Our finding that MS positive status is associated with higher risk than high FLI, and the co-occurrence
2 of MS with fatty liver is associated with the greatest risk, raises the suspicion that the MS
3 phenomenon represents a more advanced stage than FLD does, in the pathogenesis of T2D, as
4 proposed by Shibata et al [25], and suggested in recent epidemiological studies [27]. However, this
5 does not explain the population of persons with normal liver (low FLI) among people with MS.

6 The novel finding in our study is that although high FLI (FLD) is associated with increased risk incident
7 T2D, MS phenomenon, which may occur regardless of FLD, modifies this association. However, the
8 association is more clearly demonstrated when the reference group comprises of subjects with
9 normal liver and no MS. MS positive status can also predict T2D independent of FLI. In addition,
10 from our data, MS status is associated with higher risk than presence of fatty liver ($FLI \geq 60$). However,
11 FLI predicts T2D in subjects without MS. Although FLI appears to be a less efficient predictor of T2D
12 among subjects with MS, the co-presence of fatty liver and MS positive status is associated with
13 higher risk than that associated with MS alone. The reason why FLI did not predict T2D among MS
14 subjects is unclear. Our data revealed that among subjects with MS, the association conferred by
15 ggt and BMI (components variables of FLI that are not included in MS), is not significant when
16 compared with that conferred by insulin resistance and hyperglycaemia. However, this finding of
17 disparate association of FLD with T2D, by MS status, needs to be studied further.

18 Our current study findings have clinical implications. Firstly, we show that FLI, a surrogate of hepatic
19 steatosis, predicts risk of incident T2D especially in persons who are negative for MS. Secondly, the
20 association can be affected by metabolic factors or MS status. This suggests that FLD can also play
21 a role in the pathogenesis of T2D. Therefore, both FLD and MS are useful for screening risk of
22 incident T2D. From health systems perspective, because high FLI has also been associated with
23 increased risk of CVD [30], and it appears to be detectable before MS may be apparent, screening

1
2
3 1 with FLI may be more cost effective in asymptomatic persons. The finding of FLI in high category
4
5
6 2 should then prompt further evaluation for T2D and CVD.
7

8 3 Our study does have a number of limitations. Firstly, FLI as a surrogate of fatty liver does not detect
9
10 4 progression of FLD. Therefore, we are unable to differentiate the contribution of NASH and fibrosis
11
12
13 5 to the observed association. Another limitation of the study is that the hepatitis B and hepatitis C
14
15 6 statuses of the subjects were not established at baseline. The prevalence rate of hepatitis B and
16
17
18 7 hepatitis C, however, have remained low in the Finnish population (Karvonen 2016) (Safreed-
19
20 8 Harmon 2018). Also, our study population comprised of men only. There are reports that suggest
21
22
23 9 that lower FLI cut off values may apply to women [31]. We are unable to explore the influence of
24
25 10 gender on the predictability of T2D using FLI. Nevertheless, Bedogni et al., concluded that the
26
27
28 11 influence of gender in FLI is related to insulin and skinfold thickness, and probably insignificant [7].
29
30 12 The strength of our study lies in the prospective design. With this, we are able to demonstrate the
31
32
33 13 ability of FLI, a surrogate of hepatic steatosis, to predict incident occurrence of T2D. We have also
34
35 14 adjusted for a range of constitutional factors, lifestyle factors and biomarkers keeping in cognizance
36
37
38 15 the components of both major exposure variables, to control for the possible confounding factors
39
40 16 in the predictability of T2D using FLI.
41
42

43 17
44
45

46 18
47
48

49 19
50
51

52 20
53
54

55 21
56
57

58 22
59
60

1 2 3 1 **CONCLUSION**

4
5
6 2 In conclusion, our data show that high FLI category (FLD) is associated with increased risk of incident
7
8 3 T2D in men without MS. Persons with high FLI should be further evaluated for FLD and, if FLD is
9
10 4 present, they should be evaluated and monitored for T2D. FLD assessed using FLI can be used as
11
12 5 additional screening tool for persons at increased risk of incident T2D in the general population.
13
14 6 Both FLI and MS are useful, and can complement each other in screening and surveillance of persons
15
16 7 at increased risk of T2D. In such persons, appropriate preventive or treatment measures should be
17
18 8 instituted to improve their prognoses.
19
20
21
22

23 9 24 25 10 **Competing interests:**

26
27
28 11 The authors declare that they have no competing interests.
29
30
31

32 12 **Authors' contributions:**

33
34
35 13 OOO and T-PT conceived the study. OOO and T-PT designed the study. OOO performed the
36
37 14 statistical analyses. OOO wrote the first draft of the manuscript. JV, JP and T-PT contributed towards
38
39 15 development of this manuscript. All authors reviewed the final draft of the manuscript.
40
41
42

43 16 **Data sharing statement:**

44
45
46 17 No additional data are available. The raw data are not available for distribution because they contain
47
48 18 sensitive health information, which cannot be distributed.
49
50

51 19 **Acknowledgements:**

52
53
54 20 OOO received study grant from the Finnish Cultural Foundation Central, Finland (Suomen
55
56 21 Kulttuurirahasto), in partial support for the conduct of this study. The foundation had no role in the
57
58 22 design, conduct or publication of the study.
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Language editing was by Enembe O Okokon MBBch., MSc., FMCPH., PhD.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

For peer review only

1
2
3 **1 REFERENCES**
4
5
6

- 7 2 1 Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver
8 3 disease—Meta-analytic assessment of prevalence, incidence, and outcomes, *Hepatology*
9 4 2016;64:73-84.
- 10
11 5 2 Kwon Y, Oh S, Hwang S, et al. Association of nonalcoholic fatty liver disease with components of
12 6 metabolic syndrome according to body mass index in Korean adults, *Am J Gastroenterol*
13 7 2012;107:1852.
- 14
15
16 8 3 Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus—
17 9 present and future perspectives, *Nature Reviews Endocrinology* 2012;8:228-36.
- 18
19
20 10 4 Perseghin G. The role of non-alcoholic fatty liver disease in cardiovascular disease, *Dig Dis*
21 11 2010;28:210-3.
- 22
23
24 12 5 Musso G, Gambino R, Cassader M, et al. Meta-analysis: natural history of non-alcoholic fatty liver
25 13 disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity, *Ann Med*
26 14 2011;43:617-49.
- 27
28
29 15 6 Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty
30 16 liver disease: Practice Guideline by the American Association for the Study of Liver Diseases,
31 17 American College of Gastroenterology, and the American Gastroenterological Association,
32 18 *Hepatology* 2012;55:2005-23.
- 33
34
35 19 7 Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of
36 20 hepatic steatosis in the general population, *BMC Gastroenterol* 2006;6:33.
- 37
38 21 8 Fedchuk L, Nascimbeni F, Pais R, et al. Performance and limitations of steatosis biomarkers in
39 22 patients with nonalcoholic fatty liver disease, *Aliment Pharmacol Ther* 2014;40:1209-22.
- 40
41
42 23 9 Jung C, Lee W, Hwang J, et al. Assessment of the fatty liver index as an indicator of hepatic
43 24 steatosis for predicting incident diabetes independently of insulin resistance in a Korean
44 25 population, *Diabetic Med* 2013;30:428-35.
- 45
46
47 26 10 Onat A, Can G, Kaya A, et al. Fatty liver disease: Disparate predictive ability for cardiometabolic
48 27 risk and all-cause mortality, *World J Gastroenterol* 2015;21:13555-65.
- 49
50 28 11 Salonen JT. Is there a continuing need for longitudinal epidemiologic research? The Kuopio
51 29 Ischaemic Heart Disease Risk Factor Study, *Ann Clin Res* 1988;20:46-50.
- 52
53
54 30 12 Salonen JT, Seppanen K, Nyyssonen K, et al. Intake of mercury from fish, lipid peroxidation, and
55 31 the risk of myocardial infarction and coronary, cardiovascular, and any death in eastern Finnish
56 32 men, *Circulation* 1995;91:645-55.
- 57
58
59 33 13 Räsänen J, Kauhanen J, Lakka T, et al. Religious affiliation and all-cause mortality: a prospective
60 34 population study in middle-aged men in eastern Finland, *Int J Epidemiol* 1996;25:1244-9.

- 1
2
3 1 14 Laukkanen JA, Pukkala E, Rauramaa R, et al. Cardiorespiratory fitness, lifestyle factors and
4 2 cancer risk and mortality in Finnish men, *Eur J Cancer* 2010;46:355-63.
5
6
7 3 15 Willenbring ML, Massey SH, Gardner MB. Helping Patients Who Drink Too Much: An Evidence-
8 4 Based Guide for Primary Care Physicians. *Am Fam Physician* 2009;80.
9
10 5 16 McGuire S. U.S. Department of Agriculture and U.S. Department of Health and Human Services,
11 6 Dietary Guidelines for Americans, 2010. 7th Edition, Washington, DC: U.S. Government Printing
12 7 Office, January 2011, *Adv Nutr* 2011;2:293-4.
13
14
15 8 17 Fawehinmi TO, Ilomäki J, Voutilainen S, et al. Alcohol consumption and dietary patterns: the
16 9 FinDrink study, *PLoS One* 2012;7:e38607.
17
18
19 10 18 Virtanen JK, Mursu J, Tuomainen TP, et al. Dietary fatty acids and risk of coronary heart disease
20 11 in men: the Kuopio Ischemic Heart Disease Risk Factor Study, *Arterioscler Thromb Vasc Biol*
21 12 2014;34:2679-87.
22
23
24 13 19 Kauhanen J, Kaplan GA, Goldberg DE, et al. Pattern of alcohol drinking and progression of
25 14 atherosclerosis, *Arterioscler Thromb Vasc Biol* 1999;19:3001-6.
26
27 15 20 Alberti K. International Diabetes Federation Task Force on Epidemiology and Prevention;
28 16 National Heart, Lung, and Blood Institute; American Heart Association; Wo, *Circulation*
29 17 2009;120:1640-5.
30
31
32 18 21 Cheema JR. Some general guidelines for choosing missing data handling methods in educational
33 19 research, *Journal of Modern Applied Statistical Methods* 2014;13:3.
34
35
36 20 22 Jäger S, Jacobs S, Kröger J, et al. Association between the fatty liver index and risk of type 2
37 21 diabetes in the EPIC-Potsdam Study, *PLoS one* 2015;10:e0124749.
38
39 22 23 Nishi T, Babazono A, Maeda T, et al. Evaluation of the fatty liver index as a predictor for the
40 23 development of diabetes among insurance beneficiaries with prediabetes, *Journal of diabetes*
41 24 *investigation* 2015;6:309-16.
42
43
44 25 24 Balkau B, Lange C, Vol S, et al. Nine-year incident diabetes is predicted by fatty liver indices: the
45 26 French D.E.S.I.R. study, *BMC Gastroenterol* 2010;10:56,230X-10-56.
46
47
48 27 25 Shibata M, Kihara Y, Taguchi M, et al. Nonalcoholic fatty liver disease is a risk factor for type 2
49 28 diabetes in middle-aged Japanese men, *Diabetes Care* 2007;30:2940-4.
50
51 29 26 Bedogni G, Bellentani S. Fatty liver: how frequent is it and why, *Ann Hepatol* 2004;3:63-5.
52
53
54 30 27 Karajamaki AJ, Bloigu R, Kauma H, et al. Non-alcoholic fatty liver disease with and without
55 31 metabolic syndrome: Different long-term outcomes, *Metabolism-Clinical and Experimental*
56 32 2017;66:55-63.
57
58
59 33 28 Valenti L, Bugianesi E, Pajvani U, et al. Nonalcoholic fatty liver disease: cause or consequence of
60 34 type 2 diabetes? *Liver International* 2016;36:1563-79.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


1 29 Targher G, Byrne CD. Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for
2 type 2 diabetes and its complications, *The Journal of Clinical Endocrinology & Metabolism*
3 2013;98:483-95.

4 30 Olubamwo OO, Virtanen JK, Voutilainen A, et al. Association of fatty liver index with the risk of
5 incident cardiovascular disease and acute myocardial infarction, *Eur J Gastroenterol Hepatol*
6 2018;30:1047-54.

7 31 Yang BL, Wu WC, Fang KC, et al. External validation of fatty liver index for identifying
8 ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan, *PLoS One*
9 2015;10:e0120443.

For peer review only

Figure 1. Variation of hazard ratio of incident type 2 diabetes with baseline fatty liver index



1
2
3 **APPENDIX**4
5 **Table 1 – Association of baseline fatty liver index with incident type 2 diabetes after excluding**
6 **smokers**
7

FLI	Number of subjects (% with T2D) (IR)	Model 1 HR (95% CI)	Model 2 HR (95% CI)
FLI*	1221(22.4) (11)	1.014(1.008-1.021)	1.016(1.009-1.022)
FLI category			
≤30 (Ref.)	549 (13.5) (7)	1.000	1.000
30-<60	380(23.9) (12)	1.43(1.02-1.99)	1.69(1.23-2.33)
≥60	292(37.0) (21)	2.24(1.54-3.26)	2.38(1.65-3.44)
P-trend	-	<0.001	<0.001

4 FLI – fatty liver index, FLI* - FLI uncategorized, HR – hazard ratio. CI – confidence interval. T2D – type 2 diabetes, IR –
5 Incidence rate per 1000 person-years

6 Model 1: FLI, age, examination date, family history of diabetes, alcohol consumption per week, physical activity, fruit-
7 berry-vegetable consumption, C-reactive protein, leukocytes albumin, fibrinogen, and ferritin, systolic blood pressure,
8 diastolic blood pressure, insulin, fasting glucose, LDL, and HDL.

9 Model 2: FLI, age, examination date, family history of diabetes, alcohol consumption per week, physical activity, fruit-
10 berry-vegetable consumption, C-reactive protein, leukocytes albumin, fibrinogen, and ferritin, metabolic syndrome
11 status.

12 ^a Other independent predictors of T2D in the model were family history of diabetes, serum ferritin, alcohol
13 consumption, and fasting glucose.

14 ^b Other independent predictors of T2D in the model were family history of diabetes, serum ferritin, alcohol
15 consumption, and metabolic syndrome status. HR metabolic syndrome = 1.76(1.28-2.41).

16

17

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cohort studies

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1, 2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	2, 5
Methods			
Study design	4	Present key elements of study design early in the paper	6-8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	7, 9-10
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	9-10
		(c) Explain how missing data were addressed	9
		(d) If applicable, explain how loss to follow-up was addressed	8
		(e) Describe any sensitivity analyses	9-10
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	7 - -
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	11, Table 1 7, 9 11
Outcome data	15*	Report numbers of outcome events or summary measures over time	11, Tables 2 & 3
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9-11, Tables 2 & 3 9-11, Tables 2 & 3 NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	12, Table 4 & 5, Figure 1
Discussion			
Key results	18	Summarise key results with reference to study objectives	20
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	23-24
Generalisability	21	Discuss the generalisability (external validity) of the study results	23-24
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	25

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.